var title_f26_24_27008="Prolonged QT interval tutorial";
var content_f26_24_27008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolonged QT interval",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 101px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The corrected QT interval (QTc) is calculated by dividing the QT interval (0.60 seconds) by the square root of the RR interval (0.84 seconds). In this case, the QTc is 0.65 seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27008=[""].join("\n");
var outline_f26_24_27008=null;
var title_f26_24_27009="Lg cell ca lung CXR";
var content_f26_24_27009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph in a 52-year-old man showing a cavitary nodule in the left mid-lung, which was a large cell carcinoma at resection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27009=[""].join("\n");
var outline_f26_24_27009=null;
var title_f26_24_27010="FAST suprapubic probe position transverse";
var content_f26_24_27010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Suprapubic probe position in transverse orientation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows probe position for obtaining a transverse view of the bladder and retrovesical structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manoj Pariyadath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27010=[""].join("\n");
var outline_f26_24_27010=null;
var title_f26_24_27011="Familial colon cancer";
var content_f26_24_27011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Familial colon cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These images are from a 38-year-old man who was found to have heme positive stool. His father and two uncles died of colon cancer before the age of fifty. Panel A: The initial study was a barium enema (although a colonoscopy is more commonly used as the initial diagnostic study for heme positive stools). The barium enema reveals a filling defect in the cecum arrow). Panels B and C: A CT scan of the abdomen shows a large exophytic mass (colored in pink) involving the cecum (arrows). Panel D: Colonoscopy reveals that the large exophytic lesion occupies most of the cecum. Adenocarcinoma was confirmed by biopsy. Despite the size of the lesion, the tumor had not spread beyond the colonic wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27011=[""].join("\n");
var outline_f26_24_27011=null;
var title_f26_24_27012="Hairy tongue";
var content_f26_24_27012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hairy tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow to black elongated papillae are present on the dorsal tongue. This case occurred in association with antibiotic therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27012=[""].join("\n");
var outline_f26_24_27012=null;
var title_f26_24_27013="Desipramine: Patient drug information";
var content_f26_24_27013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Desipramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     see \"Desipramine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/16/36103?source=see_link\">",
"     see \"Desipramine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norpramin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Desipramine;",
"     </li>",
"     <li>",
"      Novo-Desipramine;",
"     </li>",
"     <li>",
"      Nu-Desipramine;",
"     </li>",
"     <li>",
"      PMS-Desipramine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eating problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat painful nerve diseases.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701906",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to desipramine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12359 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27013=[""].join("\n");
var outline_f26_24_27013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157638\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157639\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023152\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023154\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023153\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023158\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023159\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023161\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023156\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023157\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023162\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023163\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=related_link\">",
"      Desipramine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/16/36103?source=related_link\">",
"      Desipramine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_24_27014="Continuous oxygen delivery systems for infants, children, and adults";
var content_f26_24_27014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous oxygen delivery systems for infants, children, and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27014/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27014/contributors\">",
"     Pamela Bailey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27014/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27014/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27014/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27014/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/24/27014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid and effective oxygen delivery is an essential component of the care of critically ill or injured patients. A variety of systems are available to deliver oxygen to spontaneously breathing patients. Factors that influence the appropriate choice for any given situation include the dose of oxygen required and how well the patient tolerates the device. For patients who require assisted ventilation, oxygen can be delivered with either a self-inflating or flow-inflating ventilation bag.",
"   </p>",
"   <p>",
"    This topic will review various devices that are available to continuously deliver oxygen to spontaneously breathing infants, children, and adults. The amount of oxygen that each continuous system can deliver and the advantages and disadvantages of each method are discussed.",
"   </p>",
"   <p>",
"    Oxygen conserving devices (eg, Oxymizer, Helios, or Invacare-Venture), oxygen therapy for newborns, indications for long-term oxygen supplementation, the use of oxygen in hypercapnic patients, issues regarding oxygen therapy during air travel, and airway management are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21927?source=see_link\">",
"       \"Oxygen conserving devices\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link\">",
"       \"Oxygen monitoring and therapy in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"       \"Long-term supplemental oxygen therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"       \"Use of oxygen in patients with hypercapnia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"       \"Traveling with oxygen aboard commercial air carriers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"       \"Basic airway management in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONCEPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles regarding oxygen delivery include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice of system will depend upon the clinical status of the patient and the desired dose of oxygen&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef60610 \" href=\"UTD.htm?25/42/26284\">",
"       table 1",
"      </a>",
"      ). For example, a blow by system may be suitable for an alert infant or child in moderate respiratory distress that requires a low dose of oxygen. In comparison, an obtunded patient with irregular respirations needs bag-mask ventilation with as high a dose of oxygen as possible.",
"     </li>",
"     <li>",
"      Oxygen should be humidified, whenever possible, to prevent dried secretions from obstructing smaller airways.",
"     </li>",
"     <li>",
"      The effectiveness of oxygen delivery should be monitored with pulse oximetry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link&amp;anchor=H15#H15\">",
"       \"Oxygen monitoring and therapy in the newborn\", section on 'Pulse oximetry'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Young children in respiratory distress may become frightened or agitated when oxygen is administered, causing their clinical conditions to deteriorate. Therefore, they should remain in a position of comfort whenever possible. A parent or caregiver can often hold the oxygen source in proximity to or over the child's face.",
"     </li>",
"     <li>",
"      As long as oxygenation is adequate, a nasal cannula may be preferable to a face mask for delivering oxygen to confused or delirious adults.",
"     </li>",
"     <li>",
"      Uncontrolled oxygen delivery may promote hypercarbia in adults with chronic obstructive pulmonary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"       \"Use of oxygen in patients with hypercapnia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BLOW BY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blowing (or wafting) oxygen past a patient's face is not a reliable means of oxygen delivery and is not used in adults. However, this method can temporarily provide oxygen to infants and toddlers who become agitated and more distressed with other methods of oxygen delivery, particularly during the initial evaluation and treatment for a reversible cause of respiratory distress such as croup or bronchospasm.",
"   </p>",
"   <p>",
"    Blow by oxygen is typically provided with oxygen tubing, corrugated tubing, or a simple mask. Alternatively, some young children will accept blow by oxygen more readily if the end of the oxygen tubing is poked through the bottom of a Styrofoam or paper drinking cup. Blow by oxygen is typically held at a short distance from the child's face by a parent or other caregiver. Limited evidence suggests that only low concentrations of oxygen (&lt;30 percent fraction of inspired oxygen) can be provided using these systems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Self-inflating (Ambu) ventilation bags do not reliably deliver oxygen to spontaneously breathing children and should",
"    <strong>",
"     not",
"    </strong>",
"    be used to provide blow by oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. This type of system typically has a one-way valve to prevent rebreathing. Oxygen flows through the valve when the bag is squeezed. With a mask tightly applied to the face, some spontaneously breathing patients may be able to generate sufficient inspiratory pressure to overcome the valve. However, children cannot reliably accomplish this. In comparison, a flow-inflating (anesthesia) ventilation bag that is connected to an oxygen source provides a constant flow of oxygen. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Ventilation bags'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following points should be considered when providing blow by oxygen to children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen can be best delivered at a flow rate of at least 10",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      through a reservoir (ie, a simple mask or large cup) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reservoir must remain in proximity to the child's face.",
"     </li>",
"     <li>",
"      Oxygen saturation should be monitored.",
"     </li>",
"     <li>",
"      Alternative oxygen delivery systems should be considered for children who require greater than 30 percent oxygen or prolonged oxygen therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NASAL CANNULA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nasal cannula provides oxygen through oxygen supply tubing with two soft prongs that are inserted into the patient's anterior nares. Both low and high-flow oxygen delivery may be delivered by nasal cannula. Oxygen flows from the cannula into the patient's nasopharynx. Oxygen flowing into the nasopharynx mixes with room air. Consequently, the concentration of oxygen that can be delivered by these methods vary depending upon factors such as the patient's respiratory rate, tidal volume, oxygen flow rate, and extent of mouth breathing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427423\">",
"    <span class=\"h2\">",
"     Low flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;One hundred percent oxygen is typically run through a bubbler humidifier at a rate of 1 to 4",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    The oxygen concentration that is delivered varies from 25 to 40 percent, depending upon factors such as the patient&rsquo;s respiratory rate, tidal volume, and extent of mouth breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Flow rates greater than 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    are very irritating to the nares, unless the oxygen is heated and humidified. Flow rates greater than 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    are not recommended for routine use in newborns and infants because inadvertent administration of positive airway pressure may occur at higher flow rates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2427430\">",
"     'High flow'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Low flow nasal cannulae are used to deliver oxygen to an adult with a low oxygen requirement or to an infant or child with patent nares who requires low levels of supplemental oxygen and does not accept a simple mask. This system is lightweight, inexpensive, and mobile. In addition, the infant can feed without interruption of oxygen delivery. Low flow nasal cannulae are of limited use during the stabilization of acutely ill patients, since they cannot reliably deliver high concentrations of oxygen. The nares may become dry after prolonged use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427430\">",
"    <span class=\"h2\">",
"     High flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the use of nasal cannula for low flow oxygen delivery in patients with mild respiratory distress, high-flow nasal cannulae therapy involves delivery of heated and humidified oxygen via special devices (eg, Vapotherm&reg;) at rates up to 8",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    in infants and up to 40",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    in children and adults. In patients with respiratory distress or failure, humidified high-flow nasal cannula may be better tolerated than oxygen by face mask in terms of comfort and, in small studies, has been associated with better oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. However, with currently available technology, it may be difficult to measure and regulate the elevated positive end-expiratory pressures (4 cm H20 or higher) that these high-flow rates can generate. The clinical benefit of pressures provided in this manner must therefore be weighed against the risk of possible barotrauma, especially in infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MASKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masks are the most frequently used oxygen delivery system for patients who are breathing spontaneously. General considerations when using a mask include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mask should fit over the patient's nose and mouth. It is secured around the head with an elastic strap.",
"     </li>",
"     <li>",
"      A variety of sizes must be available from which to choose the proper size for any given patient.",
"     </li>",
"     <li>",
"      Transparent masks should be used whenever possible.",
"     </li>",
"     <li>",
"      Masks may be difficult to use for some patients who become more anxious and uncooperative when a mask is strapped to their face.",
"     </li>",
"     <li>",
"      Oxygen masks may pose a risk for aspiration in the vomiting patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Characteristics of the mask, mask fit, and the addition of a reservoir determine the amount of oxygen that can be delivered. The types of masks that are typically used include simple (Venturi), partial rebreathing, and nonrebreathing systems.",
"   </p>",
"   <p>",
"    In contrast to the common simple mask, the Oxymask directs oxygen towards the mouth and nose using a patented &ldquo;diffuser system&rdquo;. The ability to provide a wide range of oxygen concentration by one device and avoidance of carbon dioxide rebreathing are possible benefits for this mask although evidence is very limited [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A specialized face mask is also used for noninvasive positive pressure ventilation in patients with acute respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link&amp;anchor=H7#H7\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Interface'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Simple masks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple masks (eg, Venturi) fit loosely over the nose and mouth. With oxygen flow rates between 6 and 10",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    simple masks can provide concentrations of oxygen between 35 and 50 percent, depending on the patient's respiratory rate and the mask fit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/5,8,14\">",
"     5,8,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The plastic mask itself serves as a reservoir for oxygen that is delivered through a small-bore tube connected at the base of the mask. Exhaled gas escapes through holes (exhalation ports) on each side of the mask. Room air enters through these ports and mixes with oxygen, thereby decreasing the percentage of oxygen delivered to the patient. An oxygen flow rate greater than 5",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    is recommended to prevent rebreathing of CO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A simple mask is useful for patients who need moderate amounts of oxygen to maintain acceptable oxygen saturation. It can provide higher concentrations of oxygen than a nasal cannula. However, precise concentrations of oxygen cannot be reliably delivered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Partial rebreathing masks",
"    </span>",
"    &nbsp;&mdash;&nbsp;A partial rebreathing mask consists of a simple mask with an attached reservoir. Oxygen concentrations from 50 to 60 percent can be achieved with oxygen flow rates between 10 and 12",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With this system, air is drawn during inspiration predominantly from the fresh oxygen inflow and the reservoir. Entrainment of room air through the exhalation ports is minimized.",
"   </p>",
"   <p>",
"    Gas in the reservoir is oxygen rich, despite the fact that it contains some exhaled gas. This is because the early exhaled air that flows into the reservoir (from respiratory dead space in the mouth and upper airways) is oxygen rich and contains little carbon dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In order to maintain a high percentage of oxygen in the reservoir and minimize CO2 rebreathing, the oxygen flow rate must be adjusted to keep the reservoir from collapsing.",
"   </p>",
"   <p>",
"    A partial rebreather mask is used primarily to conserve oxygen supply (for instance, during transport) for patients who require higher oxygen concentrations. Although the concentration of oxygen that is delivered is more reliable than a simple mask, it is diluted by room air that can still be drawn into the system through the exhalation ports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonrebreathing masks",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonrebreathing mask is a mask and reservoir system modified with two valves that limit the mixing of exhaled gases and room air with the oxygen supply. With oxygen flow rates of 10 to 15",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    and a mask with a good seal, inspired oxygen concentrations of up to 95 percent can be achieved with a nonrebreather mask [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A one-way valve over one of the exhalation ports of the mask allows the egress of expired gas during exhalation and prevents room air from entering the mask during inspiration. As a safety precaution, only one of the two exhalation ports on the mask has a one-way valve. That way, the patient can still receive room air through the open port if the flow of oxygen to the mask is inadvertently interrupted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second one-way valve is located between the reservoir and the mask. It prevents flow of exhaled gas into the reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In addition, oxygen flow into the mask is adjusted to prevent collapse of the reservoir.",
"   </p>",
"   <p>",
"    A nonrebreather mask reliably supplies the highest concentration of oxygen that can be provided to a spontaneously breathing patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENCLOSURE SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enclosure systems such as oxygen hoods or tents may be used for infants or children who require prolonged administration of oxygen but cannot tolerate a nasal cannula or mask. They are not usually used in adults. Hoods and tents can also supply good humidification and temperature control. Both systems are very noisy for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hoods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen hoods are clear, plastic cylinders that encompass the infant's head. Oxygen concentrations of 80 to 90 percent can be achieved with oxygen flow rates of &ge;10 to 15",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen enters the hood through a gas inlet. Exhaled gas exits through the opening at the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hood is usually well tolerated by newborns. Infants in an oxygen hood are accessible for monitoring and other care. Most hoods are too small to use for infants older than one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen tents are clear, plastic shells that surround the child's head and upper body. Although a tent can provide up to 50 percent oxygen using high-oxygen flow rates, mixing with room air occurs whenever the tent is opened. As a result, oxygen tents are generally not a sufficient source of oxygen for children who require concentrations greater than 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen tents limit access to the child by family and clinical staff. In addition, highly humidified air typically results in the formation of mist, which obscures the patient from view, preventing the early recognition of changes in the child's condition such as cyanosis or obtundation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VENTILATION BAGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilation bags are typically used to provide oxygen and assisted ventilation, either with a mask or through an artificial airway (ie, an endotracheal tube). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .) Flow-inflating bags can be used to provide supplemental oxygen to spontaneously breathing children. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Blow by'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Self-inflating bags",
"    </span>",
"    &nbsp;&mdash;&nbsp;A self-inflating (Ambu) bag reinflates with a recoil mechanism. It does not require a gas source to re-expand. However, during reinflation with an oxygen source, room air is entrained in the system, diluting the concentration of oxygen that is delivered to the patient. Therefore, in order to consistently deliver high concentrations of oxygen, a reservoir must be attached to the bag. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link&amp;anchor=H12#H12\">",
"     \"Basic airway management in children\", section on 'Bag-mask ventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link&amp;anchor=H12#H12\">",
"     \"Basic airway management in adults\", section on 'Bag-mask ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Flow-inflating bags",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow-inflating (anesthesia) bags require a gas source to remain inflated. When oxygen is used as the source, 100 percent oxygen can be delivered to the patient. These systems are more complicated to use than a self-inflating bag. The flow of oxygen and an outlet control valve must be adjusted to ensure safe and effective ventilation. Consequently, flow-inflating bags should only be used by clinicians with specific training and experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27014/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critically ill or injured patients frequently require oxygen therapy. The choice of an oxygen delivery system will depend upon the clinical status of the patient and the desired dose of oxygen. For patients who are breathing spontaneously, the appropriate delivery system depends upon the dose of oxygen that they require and how well they tolerate the system. These patients should remain in a position of comfort whenever possible. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General concepts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blow by (wafting) oxygen can be provided with oxygen tubing, corrugated tubing, or a simple mask to infants or children who require less than 30 percent oxygen for short periods of time. Self-inflating (Ambu) bags should",
"      <strong>",
"       not",
"      </strong>",
"      be used as a source of blow by oxygen. Pulse oximetry should be monitored to ensure that oxygen is being effectively delivered. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Blow by'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A nasal cannula can deliver 25 to 40 percent oxygen, depending on the patient's respiratory rate, tidal volume, and extent of mouth breathing. Flow rates 2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      or less are recommended for infants. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nasal cannula'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A simple mask with 6 to 10",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      of oxygen flow delivers 35 to 50 percent oxygen. Partial and nonrebreathing masks with oxygen reservoirs deliver maximum concentrations of 60 and 95 percent oxygen, respectively. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Masks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enclosure systems include hoods and tents and are appropriate for infants and children. Hoods can deliver up to 90 percent oxygen and may be used for infants less than one year of age. Tents deliver less oxygen (up to 50 percent). Mist that accumulates in the tent may obscure the child from view. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enclosure systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilation bags are used to provide oxygen to patients who require assisted ventilation. A reservoir must be attached to self-inflating bags in order to provide high concentrations of oxygen. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ventilation bags'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/1\">",
"      Davies P, Cheng D, Fox A, Lee L. The efficacy of noncontact oxygen delivery methods. Pediatrics 2002; 110:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/2\">",
"      Amar D, Brodman LE, Winikoff SA, Hollinger I. An alternative oxygen delivery system for infants and children in the post-anaesthesia care unit. Can J Anaesth 1991; 38:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/3\">",
"      Kumar RM, Kabra SK, Singh M. Efficacy and acceptability of different modes of oxygen administration in children: implications for a community hospital. J Trop Pediatr 1997; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/4\">",
"      Carter BG, Fairbank B, Tibballs J, et al. Oxygen delivery using self-inflating resuscitation bags. Pediatr Crit Care Med 2005; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/5\">",
"      Bateman NT, Leach RM. ABC of oxygen. Acute oxygen therapy. BMJ 1998; 317:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/6\">",
"      Bazuaye EA, Stone TN, Corris PA, Gibson GJ. Variability of inspired oxygen concentration with nasal cannulas. Thorax 1992; 47:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/7\">",
"      Locke RG, Wolfson MR, Shaffer TH, et al. Inadvertent administration of positive end-distending pressure during nasal cannula flow. Pediatrics 1993; 91:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/8\">",
"      Myers TR, American Association for Respiratory Care (AARC). AARC Clinical Practice Guideline: selection of an oxygen delivery device for neonatal and pediatric patients--2002 revision &amp; update. Respir Care 2002; 47:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/9\">",
"      Spentzas T, Minarik M, Patters AB, et al. Children with respiratory distress treated with high-flow nasal cannula. J Intensive Care Med 2009; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/10\">",
"      Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care 2010; 55:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/11\">",
"      de Winter JP, de Vries MA, Zimmermann LJ. Clinical practice : noninvasive respiratory support in newborns. Eur J Pediatr 2010; 169:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/12\">",
"      Lee JH, Rehder KJ, Williford L, et al. Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature. Intensive Care Med 2013; 39:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/13\">",
"      Beecroft JM, Hanly PJ. Comparison of the OxyMask and Venturi mask in the delivery of supplemental oxygen: pilot study in oxygen-dependent patients. Can Respir J 2006; 13:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/14\">",
"      Milross J, Young IH, Donnelly P. The oxygen delivery characteristics of the Hudson Oxy-one face mask. Anaesth Intensive Care 1989; 17:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/15\">",
"      Jensen AG, Johnson A, Sandstedt S. Rebreathing during oxygen treatment with face mask. The effect of oxygen flow rates on ventilation. Acta Anaesthesiol Scand 1991; 35:289.",
"     </a>",
"    </li>",
"    <li>",
"     King BR, King C, Coates WC. Critical procedures. In: APLS: The Pediatric Emergency Medicine Resource, 4th, Gausche-Hill M, Fuchs S, Yamamoto L (Eds), Jones and Bartlett, Sudbury 2004. p.686.",
"    </li>",
"    <li>",
"     Shapiro BA, Harrison RA, Kacmarek RM, Cane RD. Oxygen therapy. In: Clinical Application of Respiratory Care, Year Book Medical, Chicago 1985. p.176.",
"    </li>",
"    <li>",
"     Ludwig S. Resuscitation: Pediatric basic and advanced life support. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S (Eds), Williams &amp; Wilkins, Baltimore 1993. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/19\">",
"      Boumphrey SM, Morris EA, Kinsella SM. 100% inspired oxygen from a Hudson mask-a realistic goal? Resuscitation 2003; 57:69.",
"     </a>",
"    </li>",
"    <li>",
"     Scarfone RJ. Airway adjuncts, oxygen delivery, and suctioning of the upper airway. In: Textbook of Pediatric Emergency Medicine Procedures, Henretig FM, King C (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1997. p.101.",
"    </li>",
"    <li>",
"     Thompson AE. Pediatric airway management. In: Pediatric Critical Care, 3rd, Fuhman BP, Zimmerman J (Eds), Mosby Elsevier, Philadelphia 2006. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27014/abstract/22\">",
"      Mondolfi AA, Grenier BM, Thompson JE, Bachur RG. Comparison of self-inflating bags with anesthesia bags for bag-mask ventilation in the pediatric emergency department. Pediatr Emerg Care 1997; 13:312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6394 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27014=[""].join("\n");
var outline_f26_24_27014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BLOW BY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NASAL CANNULA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2427423\">",
"      Low flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2427430\">",
"      High flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MASKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Simple masks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Partial rebreathing masks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonrebreathing masks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENCLOSURE SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hoods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VENTILATION BAGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Self-inflating bags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Flow-inflating bags",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6394|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/42/26284\" title=\"table 1\">",
"      Oxygen delivery systems",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21927?source=related_link\">",
"      Oxygen conserving devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_24_27015="Duodenal adenocarcinoma Endosc";
var content_f26_24_27015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Duodenal adenocarcinoma as seen on upper endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Irregular ulcerated mass in the third portion of the duodenum as seen on upper gastrointestinal endoscopy that was performed for work-up of iron deficiency anemia. Biopsy confirmed a moderately differentiated adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Overman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27015=[""].join("\n");
var outline_f26_24_27015=null;
var title_f26_24_27016="Popliteal (Baker's) cyst";
var content_f26_24_27016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Popliteal (Baker's) cyst",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27016/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27016/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27016/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27016/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/24/27016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30937669\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal synovial cysts, also known as Baker&rsquo;s cysts, are a common occurrence in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They present as swelling in the popliteal fossa due to enlargement of the gastrocnemius-semimembranosus bursa, which lies between these two muscles on the medial side of the fossa slightly distal to the center crease in the back of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Popliteal cysts in adults are often secondary to degenerative or inflammatory joint disease or joint injury; they usually communicate with the adjacent knee joint space, especially in older patients with knee pathology. Communicating cysts contain synovial fluid. In children, popliteal cysts are usually a primary process, arising directly from the gastrocnemius-semimembranosus bursa; they do not communicate with the joint space. (See",
"    <a class=\"local\" href=\"#H171882322\">",
"     'Popliteal (Baker's) cyst in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, diagnosis, and management of popliteal (Baker&rsquo;s) cyst will be presented here. The clinical and radiographic evaluation of knee pain is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=see_link\">",
"     \"Knee bursitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12489?source=see_link\">",
"     \"Radiologic evaluation of the acutely painful knee in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25385?source=see_link\">",
"     \"Radiologic evaluation of the chronically painful knee in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30937676\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most popliteal cysts are asymptomatic and are detected incidentally by an imaging study performed for some other reason. They tend to occur in adults from ages 35 to 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the prevalence of popliteal cysts varies based upon the imaging technique used, the age of the patient population,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    whether the cyst is secondary or primary.",
"   </p>",
"   <p>",
"    The prevalence ranges from 5 to 40 percent using magnetic resonance imaging (MRI) among adults with suspected internal derangement or osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]; in a similar adult population, it ranged from 23 to 32 percent by arthrography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence increases with age, possibly because",
"    <span class=\"nowrap\">",
"     knee/bursal",
"    </span>",
"    communications increase in prevalence with age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/10\">",
"     10",
"    </a>",
"    ]. There is no consistent difference in frequency between the sexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22471952\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of factors that contribute to the development and maintenance of most popliteal cysts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Joint-cyst communication, which has been documented by cadaveric dissections, at the time of arthroscopy, and by injecting dye directly into these structures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A valve-like effect between the knee joint space and the cyst, which is controlled by gastrocnemius-semimembranosus muscle changes with knee flexion and extension. This contributes to sequestration of synovial fluid in the popliteal fossa [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/11\">",
"       11",
"      </a>",
"      ]. The communicating space is open in flexion, but the tense gastrocnemius-semimembranosus muscles close this pathway in extension.",
"     </li>",
"     <li>",
"      Negative intraarticular knee pressure during partial knee flexion (minus 6 mmHg), compared with a positive pressure (16 mm Hg) during extension. These pressure changes help direct the synovial fluid flow from the suprapatellar bursa toward the knee during flexion and toward the cyst [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/11\">",
"       11",
"      </a>",
"      ]. Bursal pressure exceeds joint pressure during extension, but the flow of synovial fluid is blocked by the valve-like effect just described.",
"     </li>",
"     <li>",
"      Enlargement of the gastrocnemius-semimembranosus bursa from repeated small traumas of the bursa related to muscle contraction",
"     </li>",
"     <li>",
"      Joint capsule herniation into the popliteal fossa [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2,6\">",
"       2,6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630401051\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of popliteal cysts in adults include a history of trauma, noted in about one-third of patients, or a history of coexistent joint disease, seen in about two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/5\">",
"     5",
"    </a>",
"    ]. The most common knee disorders include osteoarthritis (OA), rheumatoid arthritis, and meniscal tears. The presence of popliteal cysts among patients with OA was unrelated to the radiographic severity of the arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/8\">",
"     8",
"    </a>",
"    ]. Popliteal cysts may also be seen in other joint disorders, such as infectious arthritis or pigmented villonodular synovitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30937684\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of a popliteal cyst are influenced by the size of the cyst, associated joint pathology, and the presence or absence of complications, such as cyst dissection or rupture. Most cysts are small, asymptomatic, not clearly evident on physical examination, and detected only by imaging studies performed because of unrelated joint symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When symptomatic, common signs and symptoms include posterior knee pain, knee stiffness, and swelling or a mass behind the knee (especially with the knee in extension). Patients frequently report discomfort with prolonged standing and with hyperflexion of the knee. Symptoms and swelling may be worsened by activity.",
"   </p>",
"   <p>",
"    Symptoms due primarily to an associated joint disease may also occur, such as instability due to internal derangement or joint pain from inflammatory arthritis or osteoarthritis. In some patients, these are the major or only symptoms present. The presentation and clinical findings of the popliteal cyst do not differ based upon the underlying pathology or associated disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10003474\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal cysts may enlarge, dissect,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rupture, resulting in compression of adjacent structures and a constellation of symptoms and signs that may resemble venous thrombosis (thrombophlebitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/12\">",
"     12",
"    </a>",
"    ]. Significant complications of popliteal cysts include pseudothrombophlebitis, leg ischemia, nerve entrapment, and compartment syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These events are uncommon, but there is a lack of data to accurately estimate their frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338109\">",
"    <span class=\"h3\">",
"     Enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tender cyst enlarging into the calf (a dissecting cyst) can result in erythema, distal edema, and a positive Homans&rsquo; sign, similar to findings in deep vein thrombosis of the lower extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enlargement of the cyst within the popliteal space (independent of dissection or rupture) can compress an adjacent vein, causing lower leg and ankle swelling due to venous obstruction. Historically, the cyst may be noted before the edema, suggesting that the swelling may be related to the cyst rather than thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338116\">",
"    <span class=\"h3\">",
"     Rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;With cyst rupture, severe pain simulates thrombosis or muscle rupture, with warmth, tenderness, and erythema of the calf. A ruptured cyst can also produce ecchymoses, which may involve the posterior calf from the popliteal fossa down to the ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/16\">",
"     16",
"    </a>",
"    ]. An ecchymotic area below the medial malleolus, termed the &ldquo;crescent sign,&rdquo; may be present. In some cases, the rupture can extend upward into the thigh or down the anterior lateral aspect of the leg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2\">",
"     2",
"    </a>",
"    ]. Cyst rupture may also be more indolent, with calf and ankle swelling developing without much pain. Ruptured popliteal cysts can occur without known joint disease or any prior history of joint pain or swelling, sometimes after strenuous exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104791191\">",
"    <span class=\"h3\">",
"     Associated complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare complications that may be seen with cyst dissection or rupture include posterior tibial nerve entrapment (resulting in calf pain and plantar numbness posteriorly), anterior compartment syndrome (causing foot drop and anterolateral lower leg swelling), posterior compartment syndrome (resulting in calf swelling with pain aggravated by passive toe extension with plantar dysesthesia with toe weakness), and popliteal artery occlusion (causing leg ischemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/12,15,18\">",
"     12,15,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2355181\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a popliteal mass, the diagnosis of a popliteal (Baker&rsquo;s) cyst can usually be based upon physical examination alone. Imaging studies are performed in some patients, particularly when there is diagnostic uncertainty and when another condition is suspected. However, imaging is usually not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2355188\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We diagnose a Baker&rsquo;s cyst by the finding of a medial popliteal mass that is most prominent with the patient standing and the knee fully extended. The swelling softens or disappears upon knee flexion to 45&deg; (defined as Foucher&rsquo;s sign), as the tension on the cyst is relieved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/19\">",
"     19",
"    </a>",
"    ]. The knee should also be examined with the patient lying supine and the knee put through an arc of motion ranging from full extension to at least 90&deg; of flexion to confirm these findings and to adequately examine the knee joint for associated pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2355195\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging, usually plain radiography and ultrasonography, should be performed if the diagnosis is uncertain on examination or if another condition is suspected. Such clinical settings may include difficulty differentiating a cystic from a solid mass on physical examination, lack of significant change with range of motion, a laterally located mass, and the absence of knee pathology. Imaging is also needed if the clinical presentation suggests vascular or neurologic compromise or possible thrombophlebitis.",
"   </p>",
"   <p>",
"    We take the following approach to imaging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of ultrasound and plain radiography of the knee as the initial imaging modalities. They are both noninvasive and easily obtained, and they provide complementary information.",
"      <br/>",
"      <br/>",
"      Ultrasound can readily identify cysts, usually as fluid-filled spaces, and shows the size and extent of the cyst in relation to adjacent soft tissue structures. Additional advantages of ultrasound include the absence of ionizing radiation and its increasing availability in the office setting. Cysts that are as small as 1 to 2 centimeters can be reliably visualized [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/20\">",
"       20",
"      </a>",
"      ]. Ultrasound can also distinguish popliteal (Baker&rsquo;s) cysts from popliteal aneurysms, ganglion cysts, or other popliteal masses. The cyst appears on ultrasound as an anechoic mass, which may include echogenic debris or septations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although a plain radiograph of the knee is of limited benefit for viewing the cyst itself, it can demonstrate joint or bone abnormalities that may be associated with the cyst. A soft tissue mass (the cyst) or a joint effusion may be seen, particularly on lateral views [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with possible thrombophlebitis or cyst-related &ldquo;pseudothrombophlebitis&rdquo; syndrome, we use ultrasound because it can image the enlarged, dissected, or ruptured cyst, as well as the venous circulation, and the findings on ultrasound correlate well with venography [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/22\">",
"       22",
"      </a>",
"      ]. It may not be possible to distinguish cyst rupture from dissection, but either can usually be detected if present [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/12\">",
"       12",
"      </a>",
"      ]. Infrequently, a complete cyst rupture may not be visualized ultrasonographically, and additional studies such as magnetic resonance imaging (MRI) may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest MRI of the knee if an internal derangement is suspected and surgery is being considered, or when the diagnosis is uncertain after ultrasonography. For example, we perform magnetic resonance imaging with contrast to differentiate a tumor from a popliteal cyst with debris if a solid component is detected in a popliteal mass on ultrasound or if greater definition of the mass is required. MRI provides high quality images of the popliteal space, the cyst, and associated structures. It can also define intraarticular knee pathology, such as a meniscal or ligamentous injury, which ultrasound cannot, and it does not expose patients to ionizing radiation. On MRI, the cyst shows high signal on T2-weighted, short T1 inversion recovery (STIR), and proton density sequences. (See",
"      <a class=\"local\" href=\"#H22472104\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      MRI provides better soft tissue contrast and multi-planar imaging capability than other imaging methods; thus, it is the technique of choice in patients who require further study following ultrasound and plain radiography to confirm the cystic nature of the lesion, to evaluate the anatomical relationship to the joint and surrounding tissues, and to identify associated intra-articular disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other imaging techniques that are rarely used to detect or characterize a popliteal cyst include arthrography and computerized tomography [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2,21,24\">",
"       2,21,24",
"      </a>",
"      ]. We prefer the imaging techniques previously described.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cysts that occur only as the result of arthrographically-induced distention of the joint and a normal communicating bursa are not considered true popliteal cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22472104\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal disorders that mimic many of the clinical features of a Baker&rsquo;s cyst include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep vein thrombosis",
"     </li>",
"     <li>",
"      Cystic masses, including synovial cysts and ganglion cysts",
"     </li>",
"     <li>",
"      Solid masses, including sarcomas and lymphoma",
"     </li>",
"     <li>",
"      Popliteal artery aneurysms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is especially important to distinguish between the infrequently occurring symptoms of pseudothrombophlebitis caused by a popliteal cyst and symptoms resulting from a true deep vein thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14615843\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep vein thrombosis (DVT) may be difficult to distinguish on clinical grounds alone from &ldquo;pseudothrombophlebitis&rdquo; resulting from a markedly enlarged, dissected, or ruptured Baker&rsquo;s cyst. Either may cause swelling, warmth, tenderness, and a positive Homan&rsquo;s sign. An enlarged or ruptured cyst may also cause venous compression and an increased risk of a DVT occurring together with the cyst. (See",
"    <a class=\"local\" href=\"#H10003474\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical findings favoring the diagnosis of pseudothrombophlebitis rather than DVT include the presence of knee pain and swelling, inflammatory joint disease or other knee pathology, a knee effusion, and the absence of a cord or deep venous tenderness on examination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. The distinction between pseudothrombophlebitis and a DVT can usually be made with ultrasound studies to identify a cyst, if present, and to evaluate for possible venous disease. The diagnostic considerations should be reviewed with the radiologist prior to the study as the specific techniques for the diagnosis of deep vein thrombosis differ from those used for the evaluation of a popliteal cyst alone. (See",
"    <a class=\"local\" href=\"#H2355195\">",
"     'Imaging studies'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2576295\">",
"    <span class=\"h2\">",
"     Other cystic masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cystic masses may occur around the knee and extend posteriorly, mimicking a Baker&rsquo;s cyst, including ganglia, meniscal cysts, pes anserine bursitis, bursitis of the tibial collateral ligament, and cruciate ligament cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/21\">",
"     21",
"    </a>",
"    ]. These cysts can be distinguished on ultrasound imaging from popliteal Baker&rsquo;s cysts by their failure to extend between the gastrocnemius and semitendinosus tendons. In patients in whom a solid component is detected in a popliteal mass on ultrasound, magnetic resonance imaging with contrast can help differentiate a tumor from a popliteal cyst with debris. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41223?source=see_link&amp;anchor=H2#H2\">",
"     \"Ganglia and nodules\", section on 'Ganglia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25385?source=see_link&amp;anchor=H11#H11\">",
"     \"Radiologic evaluation of the chronically painful knee in adults\", section on 'Bursitis and cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23945277\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discrete masses in the popliteal fossa, such as lipomas, liposarcomas, or other solid tumors, are uncommon but can often be distinguished from popliteal cysts using ultrasound or other imaging techniques. In patients with a solid component detected by ultrasound, we obtain magnetic resonance imaging with contrast if greater definition of the mass is required and to distinguish the solid mass of a tumor from a popliteal cyst with debris. A positive Foucher&rsquo;s sign of softening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of decreased size of a popliteal cyst with knee flexion is consistent with, but not specific for, a Baker&rsquo;s cyst. (See",
"    <a class=\"local\" href=\"#H2355188\">",
"     'Physical examination'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31063?source=see_link\">",
"     \"Radiologic evaluation of knee tumors in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pigmented villonodular synovitis is a rare cause of a popliteal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=see_link&amp;anchor=H5#H5\">",
"     \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\", section on 'Pigmented villonodular synovitis/tenosynovial giant cell tumor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23945285\">",
"    <span class=\"h2\">",
"     Popliteal aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A popliteal artery aneurysm may present as a mass in the popliteal fossa, but it is usually pulsatile on examination and can be identified as a vascular structure by ultrasound or other imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link\">",
"     \"Popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30937698\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of symptomatic popliteal cysts includes treatment of the underlying joint disorder (when present), arthrocentesis, and intraarticular injection of the affected joint with glucocorticoids. This approach is based upon multiple case series and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/1,2,12,15,27-30\">",
"     1,2,12,15,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic cysts found incidentally do not require treatment. We advise patients with asymptomatic cysts that there is a small risk of future cyst rupture. Patients should return if a cyst becomes symptomatic and should promptly seek further medical attention if they develop signs or symptoms of the pseudothrombophlebitis syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2112147\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all patients with symptomatic cysts, we treat any underlying joint disorder that may be present, such as osteoarthritis, rheumatoid arthritis, or meniscal injury, which is causing the increased synovial fluid and enlarged cyst. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H14#H14\">",
"     \"Meniscal injury of the knee\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104791067\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treating adult patients with symptomatic, painful cysts, with or without calf involvement, with arthrocentesis of the knee and intraarticular injection with glucocorticoids (eg, 40 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide) using the same approach as that for osteoarthritis or rheumatoid arthritis. A significant decrease in the size of the cyst",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discomfort is observed in approximately two-thirds of patients within two days to a week from the time of injection in various case series, which is consistent with our experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. Glucocorticoid injections into the joint space can also be effective in patients with cysts but without joint effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Control of inflammation by glucocorticoid injection can reduce the pressure gradient between the joint and the cyst, can lead to symptomatic improvement, and can reduce the risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/2,12,15,27\">",
"     2,12,15,27",
"    </a>",
"    ]. There are no randomized trials that have compared glucocorticoid injections with alternative treatment. In an uncontrolled series of 30 patients with osteoarthritis and a popliteal cyst that were treated with intraarticular glucocorticoid injections (40 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide) and evaluated at baseline and four weeks following injection by ultrasound, the treatment was associated with a reduction in cyst size in all patients and with complete disappearance of the cyst in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with a torn meniscus or other internal derangement, we also perform arthrocentesis and a glucocorticoid injection, which may provide temporary relief until a more definitive procedure can be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H14#H14\">",
"     \"Meniscal injury of the knee\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2112233\">",
"    <span class=\"h2\">",
"     Treatment of cyst complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with possible cyst complications, such as pseudothrombophlebitis or syndromes related to the compression of adjacent vascular structures or nerves, we perform the appropriate studies needed to diagnose and treat such complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with features of pseudothrombophlebitis due to dissecting or ruptured cysts should be treated with rest, elevation, and analgesics. We also perform arthrocentesis and intraarticular glucocorticoid injection of the knee in patients with this condition. (See",
"      <a class=\"local\" href=\"#H10003474\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23338109\">",
"       'Enlargement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23338116\">",
"       'Rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of venous obstruction is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with nerve entrapment caused by enlarged or ruptured cysts may respond to intraarticular glucocorticoid injections [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H104791191\">",
"       'Associated complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"       \"Overview of lower extremity peripheral nerve syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with acute compartment syndrome require immediate surgical evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"       \"Acute compartment syndrome of the extremities\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18483426\">",
"    <span class=\"h2\">",
"     Cysts resistant to initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond to an initial injection with intraarticular glucocorticoids, the initial diagnosis of a Baker&rsquo;s cyst should be re-evaluated, and additional therapeutic measures may be necessary if the diagnosis is confirmed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accuracy of the diagnosis of popliteal cyst &mdash; Imaging studies to assess the anatomy and confirm the diagnosis should be obtained. This includes ultrasonography (if not already performed) and magnetic resonance imaging in patients in whom the diagnosis remains uncertain after ultrasound alone. (See",
"      <a class=\"local\" href=\"#H22472104\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent knee pathology &mdash; The presence of a torn meniscus, other internal derangement, or persistent joint inflammation may result in failure to respond to an initial injection, persistent effusions, or recurrence of swelling after an initial response. We obtain magnetic resonance imaging in such patients to identify underlying knee pathology that may be present. A repeat injection and, if necessary, additional interventions such as arthroscopic knee surgery or treatment with more potent medical interventions should be performed to treat such patients, depending upon the underlying knee disorder, prior to considering surgical cyst excision. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H14#H14\">",
"       \"Meniscal injury of the knee\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-communicating cysts &mdash; In the infrequent adult patient who does not respond to intraarticular injection because of a lack of communication of the cyst with the joint, direct cyst aspiration and injection with glucocorticoid can be performed. (See",
"      <a class=\"local\" href=\"#H18483508\">",
"       'Direct cyst injection'",
"      </a>",
"      below.) Symptomatic non-communicating cysts that do not improve may require surgical excision.",
"     </li>",
"     <li>",
"      Absence of joint pathology &mdash; Surgical excision may rarely be required in the absence of demonstrable joint pathology. Thus, consultation with an orthopaedic surgeon should be obtained in patients with persistent symptoms or functional impairment who have no response to injection and in whom pathology in the knee cannot be identified. (See",
"      <a class=\"local\" href=\"#H104791074\">",
"       'Surgery'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18483508\">",
"    <span class=\"h3\">",
"     Direct cyst injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond to intraarticular injection, ultrasound-guided direct aspiration of popliteal cysts, followed by injection of glucocorticoids, can be performed by clinicians experienced in this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/1,2,31\">",
"     1,2,31",
"    </a>",
"    ]. However, we usually avoid this approach because of the significant risk of recurrence related to failure to address the underlying joint pathology, the thick gelatinous character of the fluid that makes it difficult to aspirate, and the proximity of neurovascular structures in the popliteal fossa. In patients found to have noncommunicating cysts, this approach can be attempted prior to surgical excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104791074\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision may very infrequently be required if the cyst remains symptomatic with pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited mobility attributable to the cyst despite treatment of the underlying disorder and administration of intraarticular glucocorticoids. Generally, surgical excision should be reserved only for those cases where more conservative interventions have failed and where there is significant functional impairment that can be ascribed to the cysts. Surgical excision of popliteal cysts is typically a lengthy procedure that must provide the operator with wide visual access to fully excise the cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/1\">",
"     1",
"    </a>",
"    ]. Potential risks include difficulties with wound healing in the popliteal fossa and recurrence. Arthroscopic approaches include repair of the intraarticular abnormality with either removal of the cyst or debridement of the connecting capsular opening [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2575353\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most popliteal cysts do not cause symptoms or complications. Some cysts resolve without any intervention, and most respond to treatment of associated disorders of the knee joint. A glucocorticoid injection is usually beneficial in patients with arthritis that can be controlled medically, but cysts often recur in patients with underlying joint pathology that is not adequately treated. Surgical excision is not a definitive procedure, and cysts may recur after surgery because of the underlying joint abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171882322\">",
"    <span class=\"h1\">",
"     POPLITEAL (BAKER'S) CYST IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several features of popliteal (Baker&rsquo;s) cysts in children differ from those seen in adults. In children, popliteal cysts are usually a primary process, arising directly from the gastrocnemius-semimembranosus bursa, and they do not communicate with the joint space. In contrast, popliteal cysts that occur in children with internal derangements due to injury or with inflammatory arthritis resemble those in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/4,32-34\">",
"     4,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak prevalence of popliteal cysts in children is from four to seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/4\">",
"     4",
"    </a>",
"    ]. The prevalence on ultrasound examination was 2.4 percent in a study of asymptomatic children and over 50 percent in a cohort of children with juvenile idiopathic arthritis (JIA) presenting with knee effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The prevalence was 6.3 percent on MRI in a study of children referred primarily for knee pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27016/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with primary cysts usually do not require treatment but are often managed in collaboration with an orthopaedic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/6/35937?source=see_link\">",
"       \"Patient information: Baker&rsquo;s (popliteal) cyst (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104791422\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Popliteal synovial cysts (Baker&rsquo;s cysts) in adults generally arise in association with underlying joint disease, such as degenerative or inflammatory arthritis or joint injury. The cyst forms as an enlargement of the gastrocnemius-semimembranosus bursa, which lies between these two muscles on the medial side of the fossa slightly distal to the center crease of the back of the knee.",
"      <br/>",
"      <br/>",
"      In adults, the cysts are usually in communication with the adjacent knee joint space. The development and maintenance of the cyst is influenced by communication between the posterior joint capsule and the bursa, a pressure gradient favoring movement of synovial fluid towards the cyst, and a valve-like effect between the knee joint space and the cyst. This effect is controlled by gastrocnemius-semimembranosus muscle changes with knee flexion and extension by which fluid is sequestered in the popliteal fossa. (See",
"      <a class=\"local\" href=\"#H22471952\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H630401051\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary cysts, the usual form in children, arise directly from the gastrocnemius-semimembranosus bursa but do not communicate with the joint space. (See",
"      <a class=\"local\" href=\"#H30937669\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30937676\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posterior knee pain, knee stiffness, and detection of swelling or a mass behind the knee are the most commonly noted symptoms, although most cysts are small, are asymptomatic, and are only noted incidentally. The cysts are typically more prominent when the knee is in extension. Symptoms from associated joint disease may be the major or only symptoms present. (See",
"      <a class=\"local\" href=\"#H30937684\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most symptomatic cysts do not cause significant complications. However, popliteal cysts may enlarge, dissect,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rupture, resulting in compression of adjacent structures and a constellation of symptoms and signs that can resemble venous thrombosis, called pseudothrombophlebitis, including calf pain, erythema, distal edema, and a positive Homans&rsquo; sign. A ruptured cyst can also produce ecchymoses which may involve the posterior calf from the popliteal fossa down to the ankle. Infrequent complications of popliteal cysts include leg ischemia, nerve entrapment, and compartment syndromes. (See",
"      <a class=\"local\" href=\"#H10003474\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We usually diagnose popliteal cysts based upon physical examination in patients with popliteal swelling who lack signs or symptoms of cyst rupture or dissection. We examine the knee with the patient lying supine through an arc of motion ranging from full extension to at least 90&deg; of flexion. The mass, which is usually felt medially in the popliteal space and is most prominent at full knee extension, may soften or disappear on flexion to 45&deg; (Foucher&rsquo;s sign) as the tension on the cyst is relieved. (See",
"      <a class=\"local\" href=\"#H2355181\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2355188\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom the diagnosis is uncertain on examination alone or in whom the clinical presentation is consistent with pseudothrombophlebitis or vascular or neurologic compromise, we use ultrasound and plain radiography of the knee as the initial imaging modalities. We obtain MR imaging of the knee when an internal derangement is suspected and surgery is being considered or when the diagnosis is uncertain after ultrasonography. (See",
"      <a class=\"local\" href=\"#H2355195\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes deep vein thrombosis, if signs of calf pain or swelling are present; other cystic masses such as ganglia; solid tumors such as lipomas and liposarcomas; and popliteal artery aneurysms. Most of these entities can be distinguished from popliteal (Baker&rsquo;s) cysts by ultrasound imaging if suspected clinically; we perform magnetic resonance imaging if solid elements of a cyst or a mass are detected on ultrasonography. (See",
"      <a class=\"local\" href=\"#H22472104\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We manage popliteal cysts in adults primarily by treating the underlying intraarticular inflammatory or degenerative process associated with the cyst. In patients with painful symptomatic cysts, despite usual management of their joint disease, or those in whom temporary relief of symptoms would be of benefit prior to a more definite procedure (eg, in patients with a meniscal tear), we suggest treatment with a glucocorticoid injection of the knee joint (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30937698\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H104791067\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with calf symptoms, we perform imaging, usually ultrasonography, to exclude deep vein thrombosis. We do not treat incidentally noted asymptomatic popliteal cysts, and children with primary cysts generally do not require treatment. We evaluate patients with symptomatic cysts resistant to these interventions for the accuracy of the diagnosis or the presence of persistent articular pathology or a noncommunicating cyst prior to direct cyst injection or referral for surgical excision. (See",
"      <a class=\"local\" href=\"#H30937698\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H104791067\">",
"       'Initial therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H104791074\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/1\">",
"      Fritschy D, Fasel J, Imbert JC, et al. The popliteal cyst. Knee Surg Sports Traumatol Arthrosc 2006; 14:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/2\">",
"      Handy JR. Popliteal cysts in adults: a review. Semin Arthritis Rheum 2001; 31:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/3\">",
"      Wilson PD, Eyre-Brook AL, Francis JD. A clinical and anatomical study of the semimembranosus bursa in relation to popliteal cyst. J Bone Joint Surg 1938; 20:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/4\">",
"      GRISTINA AG, WILSON PD. POPLITEAL CYSTS IN ADULTS AND CHILDREN. A REVIEW OF 90 CASES. Arch Surg 1964; 88:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/5\">",
"      Miller TT, Staron RB, Koenigsberg T, et al. MR imaging of Baker cysts: association with internal derangement, effusion, and degenerative arthropathy. Radiology 1996; 201:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/6\">",
"      Fielding JR, Franklin PD, Kustan J. Popliteal cysts: a reassessment using magnetic resonance imaging. Skeletal Radiol 1991; 20:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/7\">",
"      Sansone V, de Ponti A, Paluello GM, del Maschio A. Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Int Orthop 1995; 19:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/8\">",
"      Hayashi D, Roemer FW, Dhina Z, et al. Longitudinal assessment of cyst-like lesions of the knee and their relation to radiographic osteoarthritis and MRI-detected effusion and synovitis in patients with knee pain. Arthritis Res Ther 2010; 12:R172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/9\">",
"      Wolfe RD, Colloff B. Popliteal cysts. An arthrographic study and review of the literature. J Bone Joint Surg Am 1972; 54:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/10\">",
"      Lindgren PG, Will&eacute;n R. Gastrocnemio-semimembranosus bursa and its relation to the knee joint. I. Anatomy and histology. Acta Radiol Diagn (Stockh) 1977; 18:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/11\">",
"      Lindgren PG, Rauschning W. Radiographic investigation of popliteal cysts. Acta Radiol Diagn (Stockh) 1980; 21:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/12\">",
"      Katz RS, Zizic TM, Arnold WP, Stevens MB. The pseudothrombophlebitis syndrome. Medicine (Baltimore) 1977; 56:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/13\">",
"      Kraag G, Thevathasan EM, Gordon DA, Walker IH. The hemorrhagic crescent sign of acute synovial rupture. Ann Intern Med 1976; 85:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/14\">",
"      Gerber NJ, Dixon AS. Synovial cysts and juxta&ndash;articular bone cysts. Semin Arthritis Rheum 1974; 3:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/15\">",
"      Hench PK, Reid RT, Reames PM. Dissecting popliteal cyst simulating thrombophlebitis. Ann Intern Med 1966; 64:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/16\">",
"      Vela P, Pascual E, Ronan J, Rosas J. Cutaneous manifestation of ruptured popliteal cyst. Clin Rheumatol 1991; 10:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/17\">",
"      Macfarlane DG, Bacon PA. Popliteal cyst rupture in normal knee joints. Br Med J 1980; 281:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/18\">",
"      Dash S, Bheemreddy SR, Tiku ML. Posterior tibial neuropathy from ruptured Baker's cyst. Semin Arthritis Rheum 1998; 27:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/19\">",
"      Canoso JJ, Goldsmith MR, Gerzof SG, Wohlgethan JR. Foucher's sign of the Baker's cyst. Ann Rheum Dis 1987; 46:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/20\">",
"      Fam AG, Wilson SR, Holmberg S. Ultrasound evaluation of popliteal cysts on osteoarthritis of the knee. J Rheumatol 1982; 9:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/21\">",
"      Torreggiani WC, Al-Ismail K, Munk PL, et al. The imaging spectrum of Baker's (Popliteal) cysts. Clin Radiol 2002; 57:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/22\">",
"      Tan SS, Chong BK, Thoo FL, et al. Diagnosis of deep venous thrombosis: accuracy of colour doppler ultrasound compared with venography. Singapore Med J 1995; 36:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/23\">",
"      Marra MD, Crema MD, Chung M, et al. MRI features of cystic lesions around the knee. Knee 2008; 15:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/24\">",
"      Levitin PM. Letter: Diagnosis of Baker cyst. JAMA 1976; 236:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/25\">",
"      Hermann G, Yeh HC, Lehr-Janus C, Berson BL. Diagnosis of popliteal cyst: double-contrast arthrography and sonography. AJR Am J Roentgenol 1981; 137:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/26\">",
"      Tatari H, Baran O, Lebe B, et al. Pigmented villonodular synovitis of the knee presenting as a popliteal cyst. Arthroscopy 2000; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/27\">",
"      Acebes JC, S&aacute;nchez-Pernaute O, D&iacute;az-Oca A, Herrero-Beaumont G. Ultrasonographic assessment of Baker's cysts after intra-articular corticosteroid injection in knee osteoarthritis. J Clin Ultrasound 2006; 34:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/28\">",
"      Nakano KK. Entrapment neuropathy from Baker's cyst. JAMA 1978; 239:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/29\">",
"      Ahn JH, Lee SH, Yoo JC, et al. Arthroscopic treatment of popliteal cysts: clinical and magnetic resonance imaging results. Arthroscopy 2010; 26:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/30\">",
"      Sansone V, De Ponti A. Arthroscopic treatment of popliteal cyst and associated intra-articular knee disorders in adults. Arthroscopy 1999; 15:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/31\">",
"      Bandinelli F, Fedi R, Generini S, et al. Longitudinal ultrasound and clinical follow-up of Baker's cysts injection with steroids in knee osteoarthritis. Clin Rheumatol 2012; 31:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/32\">",
"      Seil R, Rupp S, Jochum P, et al. Prevalence of popliteal cysts in children. A sonographic study and review of the literature. Arch Orthop Trauma Surg 1999; 119:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/33\">",
"      Szer IS, Klein-Gitelman M, DeNardo BA, McCauley RG. Ultrasonography in the study of prevalence and clinical evolution of popliteal cysts in children with knee effusions. J Rheumatol 1992; 19:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27016/abstract/34\">",
"      De Maeseneer M, Debaere C, Desprechins B, Osteaux M. Popliteal cysts in children: prevalence, appearance and associated findings at MR imaging. Pediatr Radiol 1999; 29:605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14924 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27016=[""].join("\n");
var outline_f26_24_27016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H104791422\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30937669\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30937676\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22471952\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630401051\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30937684\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10003474\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23338109\">",
"      - Enlargement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23338116\">",
"      - Rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104791191\">",
"      - Associated complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2355181\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2355188\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2355195\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22472104\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14615843\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2576295\">",
"      Other cystic masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23945277\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23945285\">",
"      Popliteal aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30937698\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2112147\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104791067\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2112233\">",
"      Treatment of cyst complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18483426\">",
"      Cysts resistant to initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18483508\">",
"      - Direct cyst injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104791074\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2575353\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H171882322\">",
"      POPLITEAL (BAKER'S) CYST IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104791422\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=related_link\">",
"      Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=related_link\">",
"      Knee bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=related_link\">",
"      Meniscal injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/6/35937?source=related_link\">",
"      Patient information: Baker&rsquo;s (popliteal) cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31063?source=related_link\">",
"      Radiologic evaluation of knee tumors in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12489?source=related_link\">",
"      Radiologic evaluation of the acutely painful knee in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25385?source=related_link\">",
"      Radiologic evaluation of the chronically painful knee in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_24_27017="Digoxin: Pediatric drug information";
var content_f26_24_27017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Digoxin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"    see \"Digoxin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/34/30245?source=see_link\">",
"    see \"Digoxin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lanoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Digoxin&reg;;",
"     </li>",
"     <li>",
"      Digoxin Injection CSD;",
"     </li>",
"     <li>",
"      Lanoxin&reg;;",
"     </li>",
"     <li>",
"      Pediatric Digoxin CSD;",
"     </li>",
"     <li>",
"      PMS-Digoxin;",
"     </li>",
"     <li>",
"      Toloxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cardiac Glycoside",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F15163298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Heart failure, atrial dysrhythmias:",
"     </b>",
"     Injection, Oral solution: Dosage must be individualized due to substantial individual variation. For management of heart failure, a lower serum digoxin concentration may be adequate compared to treatment of cardiac arrhythmias; consider doses at the lower end of the recommended range for treatment of heart failure; a digitalizing dose (loading dose) may not be necessary when treating heart failure (Ross, 2001). For management of atrial dysrhythmias, dose should be titrated to the lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The dosage tables below list dosage recommendations for normal renal function and are based upon average patient response. Total digitalizing dose should be decreased by 50% in patients with end-stage renal disease.",
"     <b>",
"      Note:",
"     </b>",
"     Total digitalizing dose should be divided (see below). If changing from oral solution to I.V. therapy, dosage should be reduced by 20% to 25%.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Initial Dosage Recommendations for Digoxin",
"      <sup>",
"       A",
"      </sup>",
"      (Digitalizing)",
"     </caption>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Total Digitalizing Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Administer in three divided doses",
"         <sup>",
"          B",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V.",
"         <sup>",
"          C",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Based on lean body weight and normal renal function for age",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          B",
"         </sup>",
"         Do not give full total digitalizing dose (TDD) at once. Give one-half of the TDD for the initial dose, then give one-quarter of the TDD for each of two subsequent doses at 6- to 8-hour intervals; prior to additional doses, clinical response should be fully evaluated (eg, ECG).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          C",
"         </sup>",
"         May also be administered I.M.; however, not usually recommended.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Preterm neonates",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Full-term neonates",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-30",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Maintenance Dosage Recommendations for Digoxin",
"      <sup>",
"       A",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Total Daily Maintenance Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Administer in equal divided doses every 12 hours",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg/day)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V.",
"         <sup>",
"          B,C",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Based on lean body weight and normal renal function for age. Decrease maintenance dose in patients with decreased renal function.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          B",
"         </sup>",
"         Daily maintenance I.V. dose is typically 20% to 30% of total I.V. digitalizing dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          C",
"         </sup>",
"         May also be administered I.M.; however, not usually recommended.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Preterm neonates",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Full-term neonates",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-8",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"      see \"Digoxin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents: Dosage must be individualized due to substantial individual variation; for management of heart failure, a lower serum digoxin concentration may be adequate compared to treatment of cardiac arrhythmias; consider doses at the lower end of the recommended range for treatment of heart failure; a digitalizing dose (loading dose) may not be necessary when treating heart failure (Ross, 2001). For management of atrial dysrhythmias, dose should be titrated to the lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     The dosage tables below list dosage recommendations for normal renal function and are based on average patient response. Total digitalizing dose should be decreased by 50% in patients with end-stage renal disease.",
"     <b>",
"      Note:",
"     </b>",
"     Total digitalizing dose should be divided (see below). If changing from oral solution or tablets to I.V. therapy, dosage should be reduced by 20% to 25%.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Initial Dosage Recommendations for Digoxin",
"      <sup>",
"       A",
"      </sup>",
"      (Digitalizing)",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Total Digitalizing Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Administer in three divided doses",
"         <sup>",
"          B",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral Solution",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tablets",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V.",
"         <sup>",
"          C",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Based on lean body weight and normal renal function for age",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          B",
"         </sup>",
"         <b>",
"          Do not give full total digitalizing dose (TDD) at once.",
"         </b>",
"         Give one-half of the TDD for the initial dose, then give one-quarter of the TDD for each of two subsequent doses at 6- to 8-hour intervals; prior to additional doses, clinical response should be fully evaluated (eg, ECG).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          C",
"         </sup>",
"         May also be administered by I.M; however, not recommended.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-24 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &minus;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-5 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &minus;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-35",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-30",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-12",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Maintenance Dosage Recommendations for Digoxin",
"      <sup>",
"       A",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Maintenance Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         If &le;10 years, administer in equal divided doses twice daily",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         If &gt;10 years, administer once daily",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/kg/day)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral Solution",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tablets",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V.",
"         <sup>",
"          B,C",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Based on lean body weight and normal renal function for age. Decrease maintenance dose in patients with decreased renal function.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          B",
"         </sup>",
"         May also be administered by I.M; however, not recommended.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          C",
"         </sup>",
"         Daily maintenance I.V. dose is typically 20% to 30% of total digitalizing I.V. dose in pediatric patients &le;24 months and 25% to 35% in older pediatric patients.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-24 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &minus;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5-12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-5 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &minus;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation (rate control) in patients with heart failure:",
"     </b>",
"     Loading dose: I.V.: 0.25 mg every 2 hours, up to 1.5 mg within 24 hours; for nonacute situations, may administer 0.5 mg orally once daily for 2 days, followed by oral maintenance dose. Maintenance dose: I.V., Oral: 0.125-0.375 mg once daily (Fuster, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heart failure: Note:",
"     </b>",
"     Loading dose not recommended; Daily maintenance dose: Oral: 0.125-0.25 mg once daily; higher daily doses (up to 0.5 mg/day) are rarely necessary. If patient is &gt;70 years old, has impaired renal function, or has a low lean body mass, low doses (eg, 0.125 mg daily or every other day) should be used (Hunt, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Supraventricular tachyarrhythmias (rate control):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: Total digitalizing dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 0.75-1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V., I.M: 0.5-1 mg (",
"     <b>",
"      Note:",
"     </b>",
"     I.M. not preferred due to severe injection site pain.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Give",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the total digitalizing dose (TDD) as the initial dose, then give",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of the TDD in each of two subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Daily maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 0.125-0.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V., I.M: 0.1-0.4 mg once daily (",
"     <b>",
"      Note:",
"     </b>",
"     I.M. not preferred due to severe injection site pain.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: Reduce by 50% in end-stage renal disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer's labeling: Dosage reductions and close monitoring recommended; see product labeling for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     -specific dosage recommendation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: The following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     GRF: 30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of normal dose at normal intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     GRF: 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of normal dose at normal intervals",
"     <b>",
"      or",
"     </b>",
"     administer normal dose every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     GRF: &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 25% of normal dose at normal intervals",
"     <b>",
"      or",
"     </b>",
"     administer normal dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Intermittent hemodialysis: Administer 25% of normal dose at normal intervals",
"     <b>",
"      or",
"     </b>",
"     administer normal dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administer 25% of normal dose at normal intervals",
"     <b>",
"      or",
"     </b>",
"     administer normal dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of normal dose at normal intervals; titrate to desired effect; monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     ESRD: If loading dose necessary, reduce by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Acute renal failure: Based on expert opinion, if patient in acute renal failure requires ventricular rate control (eg, in atrial fibrillation), consider alternative therapy. If loading digoxin becomes necessary, patient volume of distribution may be increased and reduction in loading dose may not be necessary; however, maintenance dosing will require adjustment as long as renal failure persists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 25% to 75% of normal daily dose (divided and given at normal intervals) or administer normal dose every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 10% to 25% of normal daily dose (divided and given at normal intervals) or give normal dose every 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 250 mcg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanoxin&reg;: 250 mcg/mL (2 mL) [contains ethanol 10%, propylene glycol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanoxin&reg;: 100 mcg/mL (1 mL) [contains ethanol 10%, propylene glycol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 50 mcg/mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 125 mcg, 250 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanoxin&reg;: 125 mcg, 250 mcg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer consistently with relationship to meals; avoid concurrent administration (ie, administer digoxin 1 hour before or 2 hours after) with meals high in fiber or pectin and with drugs that decrease oral absorption of digoxin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution: Only the calibrated manufacturer-provided dropper or a calibrated oral syringe should be used to measure the dose. For doses &lt;0.2 mL the manufacturer-provided dropper is not accurate and should not be used; use a calibrated oral syringe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: May be administered undiluted or diluted at least fourfold in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, or SWI (less than a fourfold dilution could lead to precipitation) and slowly administered I.V. over &ge;5 minutes (usually 5-10 minutes); avoid rapid I.V. infusion since this may result in systemic and coronary arteriolar vasoconstriction; I.M. route not usually recommended due to local irritation, pain, and tissue damage.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F160196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with KCl 20 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, and NS. May be diluted fourfold in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or SWFI for direct injection (or may be administered undiluted).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, bivalirudin, ciprofloxacin, cisatracurium, dexmedetomidine, diltiazem, doripenem, famotidine, fenoldopam, fentanyl, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), inamrinone, linezolid, meperidine, meropenem, midazolam, milrinone, morphine, nesiritide, potassium chloride, remifentanil, tacrolimus, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, amphotericin B cholesteryl sulfate complex, fluconazole, foscarnet, pantoprazole, telavancin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Insulin (regular), propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, heparin, hydralazine, milrinone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; may precipitate if diluted less than fourfold.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild to moderate heart failure (HF) (Injection, oral solution: FDA approved in all ages; Tablets: FDA approved in ages &ge;5 years and adults); chronic atrial fibrillation (rate-control) (all dosage forms: FDA approved in adults). Has also been used for fetal tachycardia with or without hydrops; to slow ventricular rate in supraventricular tachyarrhythmias such as supraventricular tachycardias (SVT), excluding atrioventricular reciprocating tachycardia (AVRT)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F160198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Digoxin may be confused with Desoxyn&reg;, doxepin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lanoxin&reg; may be confused with Lasix&reg;, levothyroxine, Levoxyl&reg;, Levsinex&reg;, Lomotil&reg;, Mefoxin&reg;, naloxone, Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lanoxin [U.S., Canada, and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F160195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Accelerated junctional rhythm, asystole, atrial tachycardia with or without block, AV dissociation, first-, second- (Wenckebach), or third-degree heart block, facial edema, PR prolongation, PVCs (especially bigeminy or trigeminy), ST segment depression, ventricular tachycardia or ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apathy, anxiety, confusion, delirium, depression, dizziness, fever, hallucinations, headache, mental disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (erythematous, maculopapular [most common], papular, scarlatiniform, vesicular or bullous), pruritus, urticaria, angioneurotic edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances (blurred or yellow vision)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Laryngeal edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Asymmetric chorea, gynecomastia, thrombocytopenia, palpitation, intestinal ischemia, hemorrhagic necrosis of the intestines, vaginal cornification, eosinophilia, sexual dysfunction, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to digoxin (rare), other forms of digitalis, or any component; ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dosage in patients with renal impairment. Use with caution in patients with sinus nodal disease (may worsen condition). Withdrawal of digoxin in patients with heart failure may lead to recurrence of heart failure symptoms (monitor carefully). Atrial arrhythmias associated with hypermetabolic states are difficult to treat (use with caution). Use with caution in patients with an acute MI (within 6 months); may increase myocardial oxygen demand. During the immediate post-MI period, digoxin administered I.V. may be used in the acute treatment of refractory atrial fibrillation/flutter (especially when HF or LV dysfunction coexists) or refractory re-entrant PSVT (Antman, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract [eg, Wolff-Parkinson-White (WPW) syndrome], digoxin use has been associated with a greater slowing of conduction in the atrioventricular node than in accessory pathways  leading to ventricular fibrillation; avoid use in such patients. Avoid use in patients with second- or third-degree heart block (except in patients with a functioning artificial pacemaker); incomplete AV block (eg, Stokes-Adams attacks) may progress to complete block with digoxin administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     HF patients with preserved left ventricular function, including patients with restrictive cardiomyopathy, constrictive pericarditis, and amyloid heart disease, may be susceptible to digoxin toxicity; avoid use unless used to control ventricular response with atrial fibrillation. Digoxin should not be used in patients with low ejection fraction, sinus rhythm, and no HF symptoms since the risk of harm may be greater than clinical benefit (Hunt, 2009). Outflow obstruction may worsen due to the positive inotropic effects of digoxin; avoid use unless used to control ventricular response with atrial fibrillation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children are more likely to experience cardiac arrhythmia as a sign of excessive dosing. The most common are conduction disturbances or tachyarrhythmia (atrial tachycardia with or without block) and junctional tachycardia. Ventricular tachyarrhythmias are less common. In infants, sinus bradycardia may be a sign of digoxin toxicity. Any arrhythmia seen in a child on digoxin should be considered as digoxin toxicity. The gastrointestinal and central nervous system symptoms are not frequently seen in children.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with hypothyroidism; higher digoxin concentrations may result. Use with caution in patients with hyperthyroidism; lower digoxin concentrations may result due to decreased absorption.",
"     <b>",
"      Note:",
"     </b>",
"     New-onset atrial fibrillation or exacerbation of ventricular arrhythmias should prompt evaluation of thyroid status. Avoid rapid I.V. administration of calcium in digitalized patients; may produce serious arrhythmias. Use with caution in patients taking strong inducers or inhibitors of P-glycoprotein (eg, cyclosporine). Upon initiation of amiodarone, propafenone, quinidine, or verapamil, the need for digoxin should be evaluated and the digoxin dose should be reduced (eg, by 50%) to avoid toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with hypoxia, hypothyroidism, acute myocarditis, electrolyte disorders, acute MI. Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy. Hypercalcemia may increase the risk of digoxin toxicity; maintain normocalcemia. Monitor for proarrhythmic effects (especially with toxicity); monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injectable product contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use injectable product containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: May decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Digoxin may enhance the adverse/toxic effect of Adenosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic, Oral Inhalation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents: May decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Alitretinoin; Altretamine; Aminoglutethimide; Anastrozole; Asparaginase (E. coli); Asparaginase (Erwinia); AzaCITIDine; Busulfan; Capecitabine; CARBOplatin; Chlorambucil; CISplatin; Cladribine; Cytarabine (Liposomal); Dacarbazine; DACTINomycin; DAUNOrubicin (Conventional); DAUNOrubicin (Liposomal); Denileukin Diftitox; DOCEtaxel; EPIrubicin; Estramustine; Etoposide; Etoposide Phosphate; Exemestane; Fludarabine; Fluorouracil (Systemic); Fluorouracil (Topical); Gemcitabine; Goserelin; Hydroxyurea; IDArubicin; Ifosfamide; Irinotecan; Letrozole; Leuprolide; Lomustine; Mechlorethamine; Megestrol; Mercaptopurine; MitoMYcin (Systemic); Mitotane; MitoXANtrone; Nilutamide; PACLitaxel; Pegaspargase; Pentostatin; Polyestradiol; Porfimer; RiTUXimab; Streptozocin; Tamoxifen; Temozolomide; Teniposide; Thioguanine; Thiotepa; Topotecan; Toremifene; Tretinoin (Systemic); Valrubicin; VinBLAStine; Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Cardiac Glycosides may diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the bradycardic effect of Cardiac Glycosides.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Cardiac Glycosides.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Colesevelam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Digoxin. Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrations, and titrate carefully due to a possible risk of elevated digoxin concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: May enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Digoxin may increase the serum concentration of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.  Management: Avoid concurrent use of digoxin when possible.  If concurrent use is necessary, reduce adult digoxin dose by 50%,  monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Digoxin. Management: Monitor serum digoxin concentrations and adjust dose as needed. In patients initiating a regimen of digoxin with etravirine, digoxin should be initiated at the lowest dose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of Digoxin. This effect is specific to digoxin administered as slow dissolution oral tablets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Cardiac Glycosides. Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lenalidomide: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. This by increasing the risk of hypokalemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Cardiac Glycosides.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Cardiac Glycosides may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV) digoxin in patients receiving milnacipran. Use caution when using oral digoxin and milnacipran together, monitoring closely for possible postural hypotension and tachycardia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May increase the serum concentration of Digoxin. Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron.  Monitor serum digoxin concentrations closely to help guide digoxin dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: May enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: May enhance the adverse/toxic effect of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: May decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Cardiac Glycosides. Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the adverse/toxic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SitaGLIPtin: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Digoxin. Management: Use the lowest possible digoxin dose when starting therapy in a patient who is being treated with telaprevir, and monitor clinical response and serum concentrations closely for further dosing adjustments.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telmisartan: May increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Meals containing increased fiber (bran) or foods high in pectin, may decrease oral absorption of digoxin; avoid natural licorice (causes sodium and water retention and increases potassium loss); maintain adequate amounts of potassium in diet to decrease risk of hypokalemia (hypokalemia may increase risk of digoxin toxicity)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9729170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Digoxin crosses the placenta and can be detected in the fetus. Digoxin is recommended as first-line in the treatment of fetal tachycardia determined to be SVT. In pregnant women with atrial fibrillation or SVT, use of digoxin is recommended (Class I recommendation; Blomstr&ouml;m-Lundqvist, 2003; Fuster, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate and rhythm, periodic ECG; follow serum potassium, magnesium, and calcium closely (especially in patients receiving diuretics or amphotericin); decreased serum potassium and magnesium, or increased serum magnesium and calcium may increase digoxin toxicity; assess renal function (serum BUN, S",
"     <sub>",
"      cr",
"     </sub>",
"     ) in order to adjust dose; obtain serum drug concentrations at least 8-12 hours after a dose, preferably prior to next scheduled dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Therapeutic drug monitoring: Digoxin serum concentrations are monitored because digoxin possesses a narrow therapeutic serum concentration range; the therapeutic endpoint is difficult to quantify and digoxin toxicity may be life-threatening. Digoxin serum concentrations should be drawn",
"     <b>",
"      at least 6-8 hours after the previous dose, regardless of route of administration (optimally 12-24 hours after a dose)",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Serum digoxin concentrations may decrease in response to exercise due to increased skeletal muscle uptake; a period of rest (eg, ~2 hours) after exercise may be necessary prior to drawing serum digoxin concentrations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Initiation of therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     <b>",
"      If a loading dose is given:",
"     </b>",
"     Digoxin serum concentration may be drawn within 12-24 hours after the initial loading dose administration. Concentrations drawn this early may confirm the relationship of digoxin plasma concentrations and response but are of little value in determining maintenance doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     <b>",
"      If a loading dose is not given:",
"     </b>",
"     Digoxin serum concentration should be obtained after 3-5 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Maintenance therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     <b>",
"      Trough",
"     </b>",
"     concentrations should be followed just prior to the next dose or at a minimum of 6-8 hours after last dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Digoxin serum concentrations should be obtained within 5-7 days (approximate time to steady-state) after any dosage changes. Continue to obtain digoxin serum concentrations 7-14 days after any change in maintenance dose.",
"     <b>",
"      Note:",
"     </b>",
"     Time to steady state will be longer in patients with decreased renal function (eg, premature neonates or patients with renal impairment). In patients with end-stage renal disease, it may take 15-20 days to reach steady-state.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Patients who are receiving electrolyte-altering medications such as diuretics, serum potassium, magnesium, and calcium should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Digoxin serum concentrations should be obtained whenever any of the following conditions occur:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Questionable patient compliance or to evaluate clinical deterioration following an initial good response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Changing renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Suspected digoxin toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Initiation or discontinuation of therapy with drugs (eg, amiodarone, quinidine, verapamil) which potentially interact with digoxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Any disease changes (eg, thyroid disease)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Digoxin therapeutic serum trough concentrations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heart failure: 0.5-0.8 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: &lt;0.5 ng/mL (SI: &lt;0.6 nmol/L); probably indicates underdigitalization unless there are special circumstances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toxic: &gt;2 ng/mL; (SI: &gt;2.6 nmol/L).",
"     <b>",
"      Note:",
"     </b>",
"     Serum concentration must be used in conjunction with clinical symptoms and ECG to confirm diagnosis of digoxin intoxication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin-like immunoreactive substance (DLIS) may cross-react with digoxin immunoassay and falsely increase serum concentrations. DLIS has been found in patients with renal and liver disease, heart failure, neonates, and pregnant women (3rd trimester).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the influx of calcium ions, from extracellular to intracellular cytoplasm by inhibition of sodium and potassium ion movement across the myocardial membranes; this increase in calcium ions results in a potentiation of the activity of the contractile heart muscle fibers and an increase in the force of myocardial contraction (positive inotropic effect); inhibits adenosine triphosphatase (ATPase); decreases conduction through the S-A and A-V nodes",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Heart rate control:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-60 minutes; dependent  upon rate of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Heart rate control:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1-6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     In adult patients with atrial fibrillation, median time to ventricular rate control in one study was 6 hours (range: 3-15 hours) (Siu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Adults: 3-4 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: By passive nonsaturable diffusion in the upper small intestine; food may delay but does not affect extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distribution phase: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Extensive to peripheral tissues; concentrates in heart, liver, kidney, skeletal muscle, and intestines. Heart/serum concentration is 70:1. Pharmacologic effects are delayed and do not correlate well with serum concentrations during distribution phase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates, full-term: 7.5-10 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Disease-related changes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hyperthyroidism: Increased V",
"     <sub>",
"      d",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hyperkalemia, hyponatremia: Decreased digoxin distribution to heart and muscle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hypokalemia: Increased digoxin distribution to heart and muscles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chronic renal failure: Decreased V",
"     <sub>",
"      d",
"     </sub>",
"     : 4-6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Decreased sodium/potassium ATPase activity: Decreased tissue binding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~25%; in uremic patients, digoxin is displaced from plasma protein binding sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via sequential sugar hydrolysis in the stomach or by reduction of lactone ring by intestinal bacteria (in ~10% of population, gut bacteria may metabolize up to 40% of digoxin dose); once absorbed, only ~16% is metabolized to 3-beta-digoxigenin, 3-keto-digoxigenin, and glucuronide and sulfate conjugates; metabolites may contribute to therapeutic and toxic effects of digoxin; metabolism is reduced with decompensated heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution: 70% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature: 61-170 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates, full-term: 35-45 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 18-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 36-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuric adults: 3.5-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolites: Digoxigenin: 4 hours; Monodigitoxoside: 3-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral tablets: 1-3 hours; oral solution: 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (50% to 70% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Nondialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/34/30245?source=see_link\">",
"      see \"Digoxin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if decreased appetite, nausea, vomiting, diarrhea, or visual changes occur; avoid the herbal medicine St John's wort. Toxicity in infants may be difficult to recognize, notify physician if weight loss, failure to thrive, abdominal pain, or behavioral disturbances occur.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, \"ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bakir M and Bilgic A, &ldquo;Single Daily Dose of Digoxin for Maintenance Therapy of Infants and Children With Cardiac Disease: Is It Reliable?&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1994, 15(5):229-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/7997427 /pubmed\" id=\"7997427 \" target=\"_blank\">",
"        7997427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bendayan R and McKenzie MW, &ldquo;Digoxin Pharmacokinetics and Dosage Requirements in Pediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1983, 2(3):224-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/6349908/pubmed\" id=\"6349908\" target=\"_blank\">",
"        6349908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, \"ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias &minus; Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in Collaboration With NASPE-Heart Rhythm Society,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 42(8):1493-531.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/14563598/pubmed\" id=\"14563598\" target=\"_blank\">",
"        14563598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Heart Rhythm Association; Heart Rhythm Society, Fuster V, et al, \"ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation &minus; Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/16904574/pubmed\" id=\"16904574\" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, \"2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johne A, Brockmoller J, Bauer S, et al, &ldquo;Pharmacokinetic Interaction of Digoxin With an Herbal Extract From St John's Wort (",
"      <i>",
"       Hypericum perforatum",
"      </i>",
"      ),&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1999, 66(4):338-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/10546917/pubmed\" id=\"10546917\" target=\"_blank\">",
"        10546917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Latifi S, Lidsky K, and Blumer JL, \"Pharmacology of Inotropic Agents in Infants and Children,\"",
"      <i>",
"       Prog Pediatr Cardiol",
"      </i>",
"      , 2000, 12(1):57-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/11114547/pubmed\" id=\"11114547\" target=\"_blank\">",
"        11114547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Gheorghiade M, Young JB, et al, \"Withdrawal of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-Converting-Enzyme Inhibitors. RADIANCE Study,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/8505940/pubmed\" id=\"8505940\" target=\"_blank\">",
"        8505940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park MK, &ldquo;Use of Digoxin in Infants and Children With Specific Emphasis on Dosage,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1986, 108(6):871-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/3012054/pubmed\" id=\"3012054\" target=\"_blank\">",
"        3012054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ross RD, \"Medical Management of Chronic Heart Failure in Children,\"",
"      <i>",
"       Am J Cardiovasc Drugs",
"      </i>",
"      , 2001, 1(1):37-44.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siu CW, Lau CP, Lee WL, et al, \"Intravenous Diltiazem Is Superior to Intravenous Amiodarone or Digoxin for Achieving Ventricular Rate Control in Patients With Acute Uncomplicated Atrial Fibrillation,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(7):2174-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/24/27017/abstract-text/19487941/pubmed\" id=\"19487941\" target=\"_blank\">",
"        19487941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13230 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27017=[""].join("\n");
var outline_f26_24_27017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160142\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052266\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163298\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052258\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160116\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160101\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052271\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160196\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052262\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052270\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160198\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160195\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052275\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052257\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052256\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160185\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160110\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052278\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160112\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729170\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052265\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052269\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052255\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052273\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052274\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052264\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=related_link\">",
"      Digoxin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/34/30245?source=related_link\">",
"      Digoxin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_24_27018="Overview of retinoblastoma";
var content_f26_24_27018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of retinoblastoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Paul L Kaufman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/24/27018/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/24/27018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoblastoma, the most common intraocular malignancy of childhood, exists in sporadic and heritable forms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Children with retinoblastoma frequently (but not always) present with leukocoria (",
"    <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Prompt referral to ophthalmology and other pediatric specialists is necessary to optimize visual outcome and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoblastoma is the most common intraocular tumor of childhood, occurring in approximately 1 in 15,000 to 1 in 16,600 live births in the United States and Northern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Between 2005 and 2009, the annual incidence of retinoblastoma in the United States among children younger than 15 years of age was 4.1 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median age at diagnosis is two years, and approximately 95 percent before the age of five (",
"    <a class=\"graphic graphic_figure graphicRef62276 \" href=\"UTD.htm?8/36/8782\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/3\">",
"     3",
"    </a>",
"    ]. However, cases of newly diagnosed retinoblastoma have been reported in children as old as 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/8-11\">",
"     8-11",
"    </a>",
"    ] and, rarely, even in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The incidence is similar in boys and girls and among blacks and whites [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-fourth of retinoblastoma cases are bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/3\">",
"     3",
"    </a>",
"    ]; bilateral disease is always heritable. In contrast, only 15 percent of unilateral cases are hereditary. Multifocal, unilateral disease is generally heritable and should prompt investigation for a germline mutation. Bilateral tumors occur more commonly among younger children, reflecting the presence of a germline mutation (the average age at diagnosis is one versus two years among cases of bilateral and unilateral retinoblastoma, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef50453 \" href=\"UTD.htm?13/3/13374\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/3,15\">",
"     3,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who have a family history of retinoblastoma or a personal or family history of 13q14 deletion or 13q deletion mosaicism have an increased risk of developing retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=see_link&amp;anchor=H19035904#H19035904\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '13q14 deletion syndrome (Retinoblastoma syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetic abnormality associated with heritable forms of retinoblastoma also is associated with an increased risk of developing second primary tumors, including osteogenic sarcoma, soft tissue sarcomas (particularly leiomyosarcoma) and malignant melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. In one study of 1604 patients with retinoblastoma, the cumulative incidence rates for second cancers 50 years after diagnosis of hereditary and nonhereditary retinoblastoma were 51 and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/21\">",
"     21",
"    </a>",
"    ]. More than 60 percent of the cancers were sarcomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Retinoblastoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, patients with heritable retinoblastoma must be closely monitored for second malignancies throughout their lives. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Long-term follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sporadic versus inherited disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of patients with retinoblastoma have bilateral disease; these are always heritable. Patients with unilateral disease also can have the heritable form of the disease; these are often multifocal, occur in the first two years of life, and account for approximately 15 percent of retinoblastoma cases. The remaining approximately 60 percent of children with retinoblastoma have the unilateral and nonheritable form of the disease.",
"   </p>",
"   <p>",
"    The inherited form of retinoblastoma requires a germline mutation that can be either familial (inherited from one of the parents) or sporadic (the result of a new germline mutation) (",
"    <a class=\"graphic graphic_figure graphicRef73602 \" href=\"UTD.htm?27/30/28131\">",
"     figure 3",
"    </a>",
"    ). Children with nonheritable retinoblastoma have new somatic mutations in one retinal cell from which the tumor arises. Less than 10 percent of new retinoblastoma patients have a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All children with an immediate family history of retinoblastoma should be screened soon after birth and then at frequent intervals by an ophthalmologist to facilitate early detection of disease and salvage of the eye and vision. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Family history'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoblastoma is caused by mutational inactivation of both alleles of the retinoblastoma (",
"    <em>",
"     RB1",
"    </em>",
"    ) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/26\">",
"     26",
"    </a>",
"    ]. This gene maps to chromosome 13q14 and encodes a nuclear protein that acts as a tumor suppressor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/25,27-29\">",
"     25,27-29",
"    </a>",
"    ]. A \"two-hit\" model has been proposed to explain the different clinical features of hereditary and nonhereditary cases of retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. In the hereditary form, a mutation at the RB1 locus is present in all cells of the individual, and a second &ldquo;hit&rdquo;, occurring later in development, affects the remaining",
"    <em>",
"     RB1",
"    </em>",
"    allele within retinal cells. These cases are at risk of multifocal and bilateral tumors. The &ldquo;hit&rdquo; may be a second mutation in the RB gene or silencing through epigenetic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In the nonhereditary form of the disease, both allelic mutations arise spontaneously in a single somatic cell of the retina, resulting in the usual clinical scenario of a unifocal, unilateral tumor (",
"    <a class=\"graphic graphic_figure graphicRef73602 \" href=\"UTD.htm?27/30/28131\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/32,36\">",
"     32,36",
"    </a>",
"    ]. Retinoblastoma demonstrates incomplete penetrance, with approximately 90 percent of genotypic carriers expressing the malignancy. Certain kindreds with hereditary retinoblastoma have been identified with much lower penetrance, possibly related to genetic modifiers or only partial inactivation of the",
"    <em>",
"     RB1",
"    </em>",
"    gene (eg, inactivation of",
"    <em>",
"     SYK",
"    </em>",
"    , a protooncogene necessary for the growth or retinoblastoma cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/34,35,37,38\">",
"     34,35,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated retinoblastoma grows to fill the eye, destroying the globe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30\">",
"     30",
"    </a>",
"    ]. Metastatic spread may begin within 4 months of diagnosis, and death can occur within a year following metastasis. Spontaneous regression may occur in a small number of cases but is a rare occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. A small tumor with surrounding chorioretinal atrophy, called a retinocytoma, can be a very rare benign manifestation of",
"    <em>",
"     RB1",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common routes of metastatic spread are direct infiltration via the optic nerve to the central nervous system, or spread via the choroid to the orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/43\">",
"     43",
"    </a>",
"    ]. There are three additional routes of spread: dispersion of the tumor cells through the subarachnoid space to the contralateral optic nerve or through the cerebrospinal fluid to the central nervous system; hematogenous dissemination to the lung, bone, or brain; and lymphatic dissemination if the tumor spreads anteriorly into the conjunctivae and eyelids, or extends into extraocular tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocoria is the most common presenting finding in children with retinoblastoma in the United States (",
"    <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"     picture 1",
"    </a>",
"    ); however, other findings may herald the disease, and leukocoria is not necessary for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In one retrospective review of 1654 patients with retinoblastoma, the most common presenting signs were leukocoria (54 percent) and strabismus (",
"    <a class=\"graphic graphic_picture graphicRef74034 \" href=\"UTD.htm?40/19/41278\">",
"     picture 2",
"    </a>",
"    ) (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because leukocoria is the most common finding of retinoblastoma, emergent referral to an ophthalmologist is warranted. The child with strabismus should also be referred urgently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation and management of strabismus in children\", section on 'Strabismus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the child with leukocoria\", section on 'Referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common presentations for retinoblastoma include decreased vision (4 percent), ocular inflammation (5 percent), and a known family history of the disease (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/4\">",
"     4",
"    </a>",
"    ]. Rare presentations include iris heterochromia, caused in some cases by neovascularization of the iris, called rubeosis iridis; vitreous hemorrhage (causing a dark rather than white light reflex) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/46\">",
"     46",
"    </a>",
"    ]; hyphema in the absence of trauma; glaucoma; anisocoria; orbital cellulitis from tumor necrosis with proptosis and eye pain; and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/4,30,47-50\">",
"     4,30,47-50",
"    </a>",
"    ]. Advanced stage disease is more common in developing countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Morphologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the classic presentation of early retinoblastoma is a solitary or multifocal, well-circumscribed translucent intraretinal mass. As the disease advances, the tumor becomes more pink in color, with dilated feeding blood vessels, and may exhibit one of three main growth patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exophytic &ndash; The vertical growth of the tumor is beneath the retina, toward and into the subretinal space, often leading to exudative retinal detachment. Tumor cells may break free and lead to subretinal seeds.",
"     </li>",
"     <li>",
"      Endophytic &ndash; The vertical growth of the tumor is toward and into the vitreous cavity. The tumor is friable, and often, the vitreous is seeded with tumor cells. Tumor cells can enter the anterior chamber and layer behind the cornea, causing a pseudo-hypopyon. Spontaneous necrosis of the tumor can lead to a severe intraocular inflammatory response, presenting as pseudo-endophthalmitis.",
"     </li>",
"     <li>",
"      Diffuse infiltrating retinoblastoma &ndash; The tumor remains relatively flat (very little vertical growth) and grows intraretinally, mimicking retinitis. The ischemia that can occur leads to iris neovascularization (and iris heterochromia) in 50 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/51\">",
"       51",
"      </a>",
"      ]. Diffuse infiltrating retinoblastoma is the least common growth pattern (occurring in approximately 2 percent of cases).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The growth pattern of retinoblastoma can vary as the tumor enlarges. An exophytic tumor can erode through the overlying retina and into the vitreous cavity, giving the clinical appearance of a combined exophytic-endophytic lesion (",
"    <a class=\"graphic graphic_picture graphicRef55803 \" href=\"UTD.htm?43/16/44302\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of retinoblastoma is increased among offspring and may be increased among siblings of a patient with retinoblastoma (the proband). The magnitude of risk among",
"    <strong>",
"     offspring",
"    </strong>",
"    of the proband depends upon the family history of retinoblastoma and tumor presentation in the proband (ie, bilateral or unilateral; multifocal or unifocal). It ranges from approximately 6 percent (if the proband has unilateral unifocal disease and a negative family history) to 50 percent (if the proband has or is assumed to have a germline mutation) (",
"    <a class=\"graphic graphic_table graphicRef68322 \" href=\"UTD.htm?27/39/28284\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The magnitude of increased risk among",
"    <strong>",
"     siblings",
"    </strong>",
"    of the proband depends upon the genetic status of the proband and the parents. It ranges from zero (if the proband clearly shows evidence mosaicism for an",
"    <em>",
"     RB1",
"    </em>",
"    mutation in non-cancer cells, such as white blood cells) to approximately 50 percent (if the parent has a germline",
"    <em>",
"     RB1",
"    </em>",
"    mutation) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/52\">",
"     52",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular genetic testing'",
"    </a>",
"    below). If molecular genetic testing is not available or is uninformative, the family history and tumor presentation (eg, unilateral versus bilateral; unifocal versus multifocal) can be used to estimate the risk, which ranges from approximately 1 to 50 percent (",
"    <a class=\"graphic graphic_table graphicRef68322 \" href=\"UTD.htm?27/39/28284\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Children at increased risk of retinoblastoma should be evaluated by an ophthalmologist shortly after birth. Screening should then be conducted every three to four months until three to four years of age, and every six months until five to six years of age (unless genetic testing of the affected child reveals that he or she does not have a germline mutation, in which case follow-up examinations are not necessary) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30\">",
"     30",
"    </a>",
"    ]. Retinoblastoma surveillance examinations are usually performed with the patient under general anesthesia to permit complete examination of the ocular fundus.",
"   </p>",
"   <p>",
"    The risk of anesthesia is balanced by the benefit of improved ocular survival. In one retrospective review of 1654 patients with retinoblastoma, those who had a positive family history and underwent surveillance for retinoblastoma from birth were diagnosed at a younger age and earlier stage of disease than those who had a positive family history and did not undergo prospective surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, prospectively screened patients had better ocular survival (71 versus 15 percent for unilateral tumors and 67 versus 43 percent for bilateral tumors).",
"   </p>",
"   <p>",
"    The recommendations for prospective surveillance among patients with a positive family history may be modified in patients in whom genetic testing revealed a non-germline mutation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of retinoblastoma can usually be made during a dilated indirect ophthalmoscopic examination that is performed under anesthesia; the characteristic finding is a chalky, white-gray retinal mass with a soft, friable consistency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30,50\">",
"     30,50",
"    </a>",
"    ]. Such an examination permits complete visualization of the retina and identification of multifocal tumors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subretinal or vitreous seeding. Pathology is necessary to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Ancillary tests, although not always necessary, may be performed to confirm the diagnosis. Ocular ultrasonography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography (CT) may demonstrate a solid intraocular tumor with characteristic intratumoral calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72561 \" href=\"UTD.htm?8/44/8898\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/53\">",
"     53",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) can be helpful to confirm the presence of an intraocular mass, particularly in those cases where Coats disease is in the differential. The funduscopic findings in patients with Coats disease and exudative retinal detachment may mimic retinoblastoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66416 \" href=\"UTD.htm?38/3/38962\">",
"     image 2",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the child with leukocoria\", section on 'Coats disease'",
"    </a>",
"    ). MRI will not demonstrate calcifications; however, it is an important modality in revealing tumor size, optic nerve involvement, and the presence of an associated intracranial lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of retinoblastoma primarily includes other conditions that produce leukocoria. The clinical features of these conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with leukocoria\", section on 'Causes of leukocoria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective series of 2775 patients referred for management of retinoblastoma over a 40-year period, 22 percent were diagnosed with other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/54\">",
"     54",
"    </a>",
"    ]. The most common conditions included Coats disease (40 percent), persistent fetal vasculature (PFV) (28 percent), vitreous hemorrhage (5 percent), and ocular toxocariasis (4 percent). The frequency of the other conditions varied depending on the age at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lt;1 year &ndash; PFV (49 percent), Coats disease (20 percent), vitreous hemorrhage (7 percent)",
"     </li>",
"     <li>",
"      1 to 2 years &ndash; Coats disease (58 percent), PFV (11 percent), vitreous hemorrhage (5 percent)",
"     </li>",
"     <li>",
"      2 to 5 years &ndash; Coats disease (61 percent), toxocariasis (8 percent), PFV (7 percent)",
"     </li>",
"     <li>",
"      &gt;5 years &ndash; Coats disease (57 percent), toxocariasis (8 percent), familial exudative vitreoretinopathy (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features (eg, age, family history, retinal mass, retinal calcification) help to distinguish these conditions from retinoblastoma. However, consultation with a retina specialist is suggested to establish the diagnosis before formulating a treatment plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation for children with retinoblastoma is individualized and is directed by the selected mode of treatment (eg, baseline complete blood count and chemistries are necessary for initiation of chemotherapy).",
"   </p>",
"   <p>",
"    For patients who present with small tumors (an uncommon presentation, except in familial cases), complete physical examination, ophthalmologic examination under anesthesia, ultrasonography, and magnetic resonance imaging (MRI) of the head and orbits are usually sufficient. Retinoblastoma is likely if calcium is present within the mass and the globe is of normal size [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Ultrasonography may show calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/58\">",
"     58",
"    </a>",
"    ]. MRI is preferred to computed tomography (CT) because of the increased long-term cancer risk associated with CT scanning, although CT is still occasionally used for diagnostically challenging cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/59-62\">",
"     59-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimaging is necessary for diagnostic confirmation and to exclude a concomitant primitive neuroectodermal tumor (PNET) in the pineal gland (ie, the so-called \"trilateral\" retinoblastoma, which consists of bilateral retinoblastomas and concomitant pineal PNET) and, in some cases, must be distinguished from benign pineal cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. In patients in whom there is a question of extension into the optic nerve or choroid,",
"    <span class=\"nowrap\">",
"     head/orbit",
"    </span>",
"    MRI with gadolinium is a better imaging choice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/62\">",
"     62",
"    </a>",
"    ]. However, imaging with gadolinium should be avoided, if possible, in patients with moderate or advanced renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic disease is rarely present at the time of diagnosis, and formal staging studies (ie, bone marrow examination, lumbar puncture,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radionuclide bone scan) are not usually performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In the usual case of endophytic retinoblastoma (in which the tumor grows toward the vitreous cavity) where the optic nerve can be seen, the risk of metastatic screening tests outweighs their likely value. Even when the globe is more than one-half full of tumor, if the optic nerve is of normal size on CT scan, many ocular oncology specialists await the pathology report before conducting metastatic screening.",
"   </p>",
"   <p>",
"    On the other hand, if there is clear evidence of tumor outside the eye (ie, optic nerve invasion, or choroidal involvement that is extensive) the full metastatic evaluation should be pursued. Symptoms and signs of metastases may include anorexia or weight loss, vomiting, headache, neurologic impairment, orbital mass, or soft tissue mass [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/69\">",
"     69",
"    </a>",
"    ]. Metastatic evaluation also should be considered in exophytic retinoblastoma, in which choroidal invasion is more frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metastatic evaluation should include a bone marrow examination (aspiration and biopsy), lumbar puncture, and radionuclide bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. When indicated, the bone marrow evaluation and lumbar puncture may be delayed until the child is under anesthesia for enucleation. Alternatively, if metastatic evaluation is not planned intraoperatively, and optic nerve infiltration is observed in the specimen after enucleation, postoperative arrangements for metastatic workup can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <em>",
"     RB1",
"    </em>",
"    gene is the only cancer gene known to be involved with retinoblastoma (though other genes may play a role in altering its expression) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/35,73\">",
"     35,73",
"    </a>",
"    ]. Molecular genetic testing is suggested for all affected patients (",
"    <a class=\"graphic graphic_table graphicRef88522 \" href=\"UTD.htm?19/23/19837\">",
"     table 2",
"    </a>",
"    ). Genetic testing can improve risk prediction and prevent unnecessary clinical screening of the patient&rsquo;s siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/74\">",
"     74",
"    </a>",
"    ]. Patients who have germline mutations should be referred to a genetic specialist for testing of parents and siblings based upon the patient's test results and empiric analysis (eg, heritable versus nonheritable, specific mutation identified, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/75\">",
"     75",
"    </a>",
"    ]. Molecular testing of peripheral white blood cells can identify the germline mutation in 90 to 95 percent of cases. In cases of unilateral disease, molecular testing should be done on tumor cells to identify the specific",
"    <em>",
"     RB1",
"    </em>",
"    mutation. The peripheral blood is then screened for this mutation, to determine if the disease is sporadic or heritable. The siblings and offspring of patients in whom germline mutations are identified should undergo genetic testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surveillance for tumor as described above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Family history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systems have been developed to classify retinoblastoma into groups according to the likelihood of globe salvage: the Reese-Ellsworth, Essen, St. Jude, Philadelphia, and the Murphree classifications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Reese-Ellsworth system was originally developed in the 1950s, and the Essen system in the 1980s. With the advent of modern examination and treatment techniques, these systems have become outdated. Retinoblastoma specialists have developed their own systems to more accurately predict the prognosis of globe salvage (eg, the Philadelphia, Murphree, and St. Jude classifications) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. The International Classification for Intraocular Retinoblastoma, based upon the Philadelphia and Murphree systems, currently is used by the Children's Oncology Group (CPG) in multicenter treatment protocols (",
"    <a class=\"graphic graphic_table graphicRef78948 \" href=\"UTD.htm?39/33/40476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various clinical and histopathologic features influence prognosis in patients with retinoblastoma. Features associated with a poor prognosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delay in diagnosis of more than six months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of intraocular surgery, which may inadvertently contribute to vitreous seeding or, more importantly, to extraocular spread [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cataract",
"     </li>",
"     <li>",
"      Use of external beam radiotherapy, which contributes to the subsequent development of secondary cancers, particularly in patients with the heritable form of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/21,86,87\">",
"       21,86,87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Choroidal, optic nerve, or orbital invasion, which increases the risk of metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/26,81,88,89\">",
"       26,81,88,89",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for extension into the optic nerve include exophytic growth pattern, elevated intraocular pressure, and tumor thickness &ge;15 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/88\">",
"     88",
"    </a>",
"    ]. Risk factors for extension into the choroid include elevated intraocular pressure and iris neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of treatment options are available for children with retinoblastoma, including several \"vision-sparing\" therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/90\">",
"     90",
"    </a>",
"    ]. The choice of treatment depends upon visual prognosis, tumor size and location, presence or absence of vitreous or subretinal seeds, and patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91\">",
"     91",
"    </a>",
"    ]. Standard therapeutic options include enucleation, external beam radiation therapy (RT), radioactive plaques (I-125 brachytherapy), cryotherapy, laser photoablation, and chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Enucleation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enucleation usually is indicated for large tumors (&gt;50 percent of globe volume) with no visual potential, blind, painful eyes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tumors that extend into the optic nerve (Group E tumors (",
"    <a class=\"graphic graphic_table graphicRef78948 \" href=\"UTD.htm?39/33/40476\">",
"     table 3",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30,91,92\">",
"     30,91,92",
"    </a>",
"    ]. Enucleation is usually the preferred treatment in eyes that have failed previous \"globe-conserving\" approaches, particularly with group E tumors. Group D tumors may require enucleation, particularly in the setting of unilateral disease. In addition, enucleation is often performed if the eye has secondary glaucoma, vitreous seeding, or anterior chamber invasion. Potential complications of enucleation include seeding of tumor cells into the orbit.",
"   </p>",
"   <p>",
"    Following enucleation, using a graduated chemotherapy approach, adjuvant chemotherapy or brachytherapy may be considered in patients with high-risk features to prevent metastatic disease (eg, iris, ciliary body, massive choroidal, or scleral infiltration, and invasion of the optic nerve posterior to the lamina cribrosa) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. In situations where there is extrascleral extension, external beam radiotherapy should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/93\">",
"     93",
"    </a>",
"    ]. Adjuvant chemotherapy may reduce the development of contralateral or intracranial tumors (PNET) in the child with a germline mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An orbital implant (typically hydroxyapatite) is placed at the time of enucleation. After the overlying conjunctiva has healed (approximately three months), a prosthesis can be fitted by an ocularist. Children who have undergone enucleation may participate in sports as long as they use proper polycarbonate protective eyewear. The need for protective eyewear to protect the socket and contralateral eye for all patients cannot be overemphasized. Participation in boxing is discouraged because protective eyewear is not permitted.",
"   </p>",
"   <p>",
"    Children who undergo enucleation for retinoblastoma must be monitored closely for orbital relapse in the two years after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/96\">",
"     96",
"    </a>",
"    ]. In a cohort of 1674 consecutive patients undergoing enucleation between 1914 and 2006, the incidence of orbital recurrence was 4.2 percent. All recurrences were diagnosed within 24 months of enucleation, and 97 percent within 12 months. The majority of patients (85 percent) with orbital recurrence also developed metastatic disease. Seventy-five percent of patients with orbital recurrence died from metastatic retinoblastoma. However, the mortality rate appears to be lower in patients diagnosed with orbital recurrence after 1984 (1 of 11 patients, 9 percent after 1984 versus 75 percent for the entire cohort).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam RT was the original globe-sparing treatment for retinoblastoma, though it is currently rarely utilized. RT may be considered for large bilateral tumors, vitreous seeding, thick tumors near the optic nerve or fovea in the eye with visual potential, or for multiple tumors that are too large for cryotherapy or laser photocoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. However, in such patients, induction chemotherapy with subsequent laser or cryotherapy (termed \"chemoreduction\") may be used as an alternative to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. The risk of tumor recurrence following external beam RT in one series of 180 tumors was 7 percent, with all recurring within 40 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major complication of external beam RT is induction of second cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/86,103-105\">",
"     86,103-105",
"    </a>",
"    ]. The increased risk of secondary cancers is seen primarily in patients with hereditary but not nonhereditary disease. In one report, the 30-year cumulative incidence of second cancers was markedly increased in the 137 patients treated with RT (35 percent, versus 6 percent in the 78 who did not receive radiation) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of radiation-induced second cancers is illustrated by the fact that more patients in the United States with hereditary retinoblastoma die of secondary tumors than of retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/86\">",
"     86",
"    </a>",
"    ]. The delayed tumorigenic potential of RT in patients with retinoblastoma has prompted changes in the management of intraocular tumors, particularly the substitution of chemotherapy for RT. However, chemotherapy alone is inadequate to cure patients with localized disease; focal therapy with thermotherapy or cryotherapy is also necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other radiation-related complications include radiation damage to the retina, optic nerve, lacrimal gland, and lens; loss of eyelashes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/107\">",
"     107",
"    </a>",
"    ]; and midface hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/108\">",
"     108",
"    </a>",
"    ]. However, with current radiation treatment techniques and delivery systems, growth retardation of the bony orbit is less common than in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radioactive plaques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioactive plaque therapy (I-125 brachytherapy), which involves securing a radioactive plaque to the eye wall at the apex of the tumor, may be used as a primary treatment or as an adjunct to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,109\">",
"     91,109",
"    </a>",
"    ]. The radiation dose is approximately 40 to 45 Gy delivered to the tumor apex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Children treated with brachytherapy usually have excellent visual outcomes, with measured vision",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    in more than one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92,110\">",
"     91,92,110",
"    </a>",
"    ]. When used appropriately, brachytherapy as primary treatment can control approximately 90 percent of tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/111\">",
"     111",
"    </a>",
"    ]. However, not all patients are candidates for brachytherapy, as the following factors must be taken into consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The tumor must be &lt;15 mm in diameter and &lt;10 mm thick",
"     </li>",
"     <li>",
"      Plaques are contraindicated if RT needs to be delivered to multiple tumor foci in each eye",
"     </li>",
"     <li>",
"      The amount of RT delivered to the optic nerve and fovea must be carefully considered, particularly if there is potential for preserved vision",
"     </li>",
"     <li>",
"      Placement of plaques can be technically difficult and requires a second surgical procedure for removal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these issues, radioactive plaques are often preferred to external beam RT in cases where both offer similar likelihood of success, since brachytherapy delivers less radiation to bone and adjacent soft tissue. This results in reduced risk for developing radiation-induced second tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92,105\">",
"     91,92,105",
"    </a>",
"    ]. In addition, the midface structures incur less tissue damage, resulting in fewer RT-related complications (such as dry socket) and an improved cosmetic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most brachytherapy is performed with I-125 plaques, although ruthenium-106 (Ru-106) is an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. A retrospective study from Germany suggests that Ruthenium-106 (Ru-106) brachytherapy should be considered for primary treatment of relatively small tumors (thickness less than 6 mm), since treatment with Ru-106 plaques reduces the radiation dose to the uninvolved retina, lens, and optic nerve, thus decreasing radiation-induced vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some states permit outpatient brachytherapy. However, most states have laws requiring individuals with implanted radioactive devices to stay in the hospital during their treatment because of the potential risk of public and environmental exposure. Children managed with brachytherapy should be monitored for the development of radiation retinopathy and optic neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cryotherapy and laser photocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laser photocoagulation can be used to treat smaller tumors (&lt;6 mm in diameter and &lt;3 mm thick) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92\">",
"     91,92",
"    </a>",
"    ] and may be used in conjunction with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92,99,100,114\">",
"     91,92,99,100,114",
"    </a>",
"    ]. If these local modalities are successful, the treated tumor usually regresses within six weeks, although it may take longer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Treatment failures or recurrences are usually treated with radioactive plaques, external beam RT, or enucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30\">",
"     30",
"    </a>",
"    ]. Complications of these methods include transient serous retinal detachment, visually significant retinal vascular occlusion, retinal traction, and preretinal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30,91,115\">",
"     30,91,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high risk of secondary radiation-induced cancers has led to efforts to replace RT with chemotherapy followed by local consolidative measures, such as cryotherapy or laser hyperthermia. Retinoblastoma is a chemotherapy-sensitive malignancy; the most active agents are",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"     carboplatin",
"    </a>",
"    combined with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    ; and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20822?source=see_link\">",
"     topotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/116-121\">",
"     116-121",
"    </a>",
"    ]. Other active agents include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the indications for chemotherapy are [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/93,94,101\">",
"     93,94,101",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vision salvage and delay or avoidance of radiotherapy in patients with bilateral disease",
"     </li>",
"     <li>",
"      Tumor shrinkage in patients with unilateral disease, good vision, and a tumor that is too large for isolated local therapy",
"     </li>",
"     <li>",
"      Metastatic disease",
"     </li>",
"     <li>",
"      Risk factors identified after enucleation (ie, massive choroid invasion or postlaminar involvement of the optic nerve)",
"     </li>",
"     <li>",
"      Trilateral retinoblastoma (bilateral retinoblastomas and concomitant pineal PNET)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chemoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most retinoblastomas are large at the time of presentation, chemoreduction is often used to reduce tumor volume, which enhances the success of local therapies. Chemoreduction has become a critical component of the initial treatment of retinoblastoma and has improved the ocular salvage rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/77,116,122-126\">",
"     77,116,122-126",
"    </a>",
"    ]. The most common chemoreduction regimen contains",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    given approximately every four weeks.",
"   </p>",
"   <p>",
"    For group E retinoblastoma, the ocular salvage rate is greater when chemoreduction is used in combination with external beam RT than when either of these modalities is used alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. In a series of patients with group E retinoblastoma, at the two-year follow-up, ocular salvage was achieved in 10 of 11 eyes (91 percent) treated with chemoreduction and prophylactic low-dose (median 2200 cGy) external beam RT compared with 29 of 55 eyes (53 percent) treated with chemoreduction alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/126\">",
"     126",
"    </a>",
"    ]. In another observational series, the ocular salvage rate among patients treated with chemoreduction and external beam RT compared to external beam RT alone was 70 versus 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/125\">",
"     125",
"    </a>",
"    ]. Among successfully treated children, preservation of visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better five years after treatment was associated with tumors at least 3 mm from the foveola and optic disc, and the absence of subretinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoreduction may also offer protection against the development of trilateral retinoblastoma. During an average of 47 months of follow-up in an observational study, none of 142 children with newly diagnosed retinoblastoma undergoing chemoreduction developed trilateral retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/128\">",
"     128",
"    </a>",
"    ]. Based upon the prevalence of trilateral retinoblastoma in a meta-analysis of published reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/65\">",
"     65",
"    </a>",
"    ], between 5 and 15 cases would have been expected. However, other reports suggest chemotherapy (specifically",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    ) may predispose to the development of secondary acute myeloid leukemia later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of treatment modality depends upon the severity of disease and the presence or absence of a germline mutation. Chemoreduction is generally considered for group A, B, and C eyes, and is less effective for group D [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/130\">",
"     130",
"    </a>",
"    ]. Following chemoreduction, these groups respond well to thermotherapy and rarely require external beam RT or enucleation. Small tumors (group A) may be treated with thermotherapy alone, particularly for unilateral cases. Plaque radiotherapy is usually offered for unilateral group B or C tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3851122\">",
"    <span class=\"h4\">",
"     Local chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of larger tumors is evolving with the development of local chemotherapy. Injection of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"     carboplatin",
"    </a>",
"    into the sub-Tenon&rsquo;s space has shown some limited success as a primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/131\">",
"     131",
"    </a>",
"    ], but longer follow-up suggests a high failure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/132\">",
"     132",
"    </a>",
"    ]. It is currently considered for possible use as a &ldquo;boost&rdquo; with chemoreduction for groups C, D, and E tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/130\">",
"     130",
"    </a>",
"    ]; however, this approach remains controversial.",
"   </p>",
"   <p>",
"    Perhaps the most provocative development has been the use of intra-arterial chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/133\">",
"     133",
"    </a>",
"    ]. An initial report of 563 cannulations of the ophthalmic artery in 187 patients with retinoblastoma suggested that direct application of chemotherapy could be safe and efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/134\">",
"     134",
"    </a>",
"    ]. In a single prospective trial of 78 patients with unilateral or bilateral retinoblastoma, two-year ocular event-free survival rates were 70 percent (95% CI 58-82 percent) for all eyes, 82 percent (95% CI 67-97 percent) for eyes that received intra-arterial chemotherapy as primary treatment, and 58 percent (95% CI 40-77 percent) for eyes that had previous treatment failure with intravenous chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    external beam radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/135\">",
"     135",
"    </a>",
"    ]. Other groups have reported successful treatment with intra-arterial chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/136-138\">",
"     136-138",
"    </a>",
"    ]. However, additional studies are necessary to define the appropriate population, regimen, and long-term safety of intra-arterial chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/139,140\">",
"     139,140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of intra-arterial chemotherapy may include eyelid edema; upper eyelid drooping; extraocular muscle dysfunction; delayed vitreous hemorrhage; potential blindness from stenosis or occlusion of the ophthalmic artery, central retinal artery, or branch retinal artery; chorioretinal atrophy; exposure to radiation (from fluoroscopy); and bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/133,137,141-144\">",
"     133,137,141-144",
"    </a>",
"    ]. Children who undergo arterial chemotherapy for treatment of retinoblastoma may require subsequent therapy, including external RT or enucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/135,145\">",
"     135,145",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Potential future therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to refining and, in some instances, combining established modalities of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/146\">",
"     146",
"    </a>",
"    ], other novel treatments continue to be investigated. Experimental protocols using transpupillary thermotherapy are currently being employed for small recurrent tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/147,148\">",
"     147,148",
"    </a>",
"    ], as are regimens employing high-dose chemotherapy with hematopoietic stem cell rescue for patients with extraocular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/146,149,150\">",
"     146,149,150",
"    </a>",
"    ]. Intravitreal chemotherapy has been successful in salvaging eyes with recurrent vitreous seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/151\">",
"     151",
"    </a>",
"    ] and may ultimately play a role in primary therapy. Intra-arterial chemotherapy has been beneficial in chemoreduction (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Chemoreduction'",
"    </a>",
"    above). With advances in the field of genetics, epigenetic modulation may become feasible treatments for retinoblastoma in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall five-year survival rate for children with retinoblastoma in the United States is 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/152\">",
"     152",
"    </a>",
"    ]. Patients who develop metastatic disease usually do so within one year of diagnosis; a child who remains recurrence free for five years after diagnosis is considered cured [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for children with metastatic disease is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/5\">",
"     5",
"    </a>",
"    ]. In most reports, 1-year to 18-month survival rates for patients with hematogenous metastases are approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/5,154-157\">",
"     5,154-157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trilateral retinoblastoma (bilateral retinoblastomas and concomitant pineal PNET) is almost universally fatal despite aggressive treatment with chemotherapy and RT, including stereotactic radiosurgery (gamma knife radiosurgery). It is the major cause of mortality in children with bilateral retinoblastoma within the first five years of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/158\">",
"     158",
"    </a>",
"    ]. In a meta-analysis of published reports of trilateral retinoblastoma, the median survival after diagnosis of trilateral retinoblastoma was nine months; survival was better among asymptomatic children with early diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for vision in bilaterally affected children depends upon the extent of tumor involvement and the effectiveness of therapy; the prognosis is better if the tumors are small and do not involve the fovea.",
"   </p>",
"   <p>",
"    The prognosis for vision in the unaffected eye of unilaterally affected children is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/30\">",
"     30",
"    </a>",
"    ]. The development of tumors in the contralateral eye after three years is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"     carboplatin",
"    </a>",
"    are at risk for hearing loss and require long-term audiometric follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H14#H14\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Carboplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the risks associated with metastatic spread from the original tumor, survivors of retinoblastoma require lifetime follow-up because of their propensity to develop (and potentially die from) secondary malignancies.",
"   </p>",
"   <p>",
"    Analyses from two large series indicate that the risk of a second malignancy is 35 to 40 percent at 50 years after the original treatment in patients with hereditary retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/24,159,160\">",
"     24,159,160",
"    </a>",
"    ]. Furthermore, this risk is markedly increased in those who were treated with radiation therapy when they were younger than one year of age compared with those who were treated with radiation therapy after one year of age or did not receive radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/86\">",
"     86",
"    </a>",
"    ]. In a meta-analysis of 676 second primary tumors reported in the literature between 1961 and 2006, the type of second primary tumors was related to age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/161\">",
"     161",
"    </a>",
"    ]. The median age for PNET was 2.7 years; for sarcomas, 13.0 years; for melanomas, 27.0 years, and for carcinomas, 29.0 years.",
"   </p>",
"   <p>",
"    Osteogenic or soft tissue sarcomas are particularly common in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/20,21,23,24,160,162\">",
"     20,21,23,24,160,162",
"    </a>",
"    ]. Many of these tumors are presumed to be radiation related, and the risk of such sarcomas appears to be related to the dose of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Retinoblastoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to soft tissue sarcomas, the incidence of common epithelial cancers (eg, bladder, lung, breast, skin) is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/21,24,103,159,160,162\">",
"     21,24,103,159,160,162",
"    </a>",
"    ]. Patients must be counseled not to smoke and to avoid exposure to other DNA-damaging agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     LONG-TERM FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up is best accomplished by a multidisciplinary team, which can minimize the number of physician visits and provide the caregivers with opportunities to discuss the full spectrum of treatment and outcomes. Some or all of the following subspecialists should be considered when creating this kind of team:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pediatric oncologist",
"     </li>",
"     <li>",
"      Pediatric endocrinologist",
"     </li>",
"     <li>",
"      Pediatric ophthalmologist",
"     </li>",
"     <li>",
"      Retina specialist",
"     </li>",
"     <li>",
"      Ocular oncologist",
"     </li>",
"     <li>",
"      Radiation oncologist",
"     </li>",
"     <li>",
"      Neuroradiologist",
"     </li>",
"     <li>",
"      Craniofacial plastic specialist",
"     </li>",
"     <li>",
"      Nurse specialist",
"     </li>",
"     <li>",
"      School specialist",
"     </li>",
"     <li>",
"      Clinical social worker",
"     </li>",
"     <li>",
"      Low-vision specialist",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk period for extraocular spread after successful treatment or enucleation is generally recognized to be 12 to 18 months. Ophthalmologic follow-up after treatment for retinoblastoma should occur at least every three months for a year. After this period of time, if stable without active retinoblastoma, the frequency of examinations can be tapered to every four and then every six months, and then annually. Routine CT or MRI scans and bone scans are probably not necessary. However, if performed, neuroimaging in patients with hereditary retinoblastoma should include images through the pineal region to look for signs of a midline PNET [",
"    <a class=\"abstract\" href=\"UTD.htm?26/24/27018/abstract/163\">",
"     163",
"    </a>",
"    ]. MRI has the advantage of minimizing radiation exposure.",
"   </p>",
"   <p>",
"    Long-term survivors should also be followed for the development of second malignancies with periodic physical examination, laboratory screening, and radiology testing, depending upon specific risk factors.",
"   </p>",
"   <p>",
"    Additional aspects of long-term follow-up are addressed in guidelines published by the",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     Children's Oncology Group",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinoblastoma is the most common intraocular tumor of childhood. The majority of cases are diagnosed in children younger than two years of age. Approximately one-fourth of cases are bilateral. Children who have a family history of retinoblastoma or a personal or family history of 13q deletion or 13q deletion mosaicism have an increased risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retinoblastoma is caused by mutational inactivation of both alleles of the retinoblastoma (",
"      <em>",
"       RB1",
"      </em>",
"      ) gene, which maps to chromosome 13q14 and encodes a nuclear protein that acts as a tumor suppressor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If untreated, retinoblastoma grows to fill the eye and destroys the internal architecture of the globe. Metastatic spread can begin within months, and death usually occurs within a matter of years following metastasis. Spontaneous regression may occur in a small number of cases but is a rare occurrence. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukocoria is the most common presenting finding but is not necessary for diagnosis. Other presentations may include strabismus, decreased vision, ocular inflammation, and family history. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children who have parents or siblings with a history of retinoblastoma should be evaluated by an ophthalmologist shortly after birth, every three to four months until three to four years of age, and every six months until five to six years of age (unless genetic testing of the affected child reveals that he or she does not have a germline mutation, in which case follow-up examinations are not necessary). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of retinoblastoma can usually be made during a dilated indirect ophthalmoscopic examination that is performed under anesthesia; the characteristic finding is a chalky, white-gray retinal mass with a soft, friable consistency. Ancillary tests may be performed to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of retinoblastoma primarily includes other conditions that produce leukocoria (eg, persistent fetal vasculature, Coats disease, and ocular toxocariasis). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H2#H2\">",
"       \"Approach to the child with leukocoria\", section on 'Causes of leukocoria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of treatment depends upon visual prognosis, tumor size and location, presence or absence of vitreous or subretinal seeds, and patient age. Standard therapeutic options include enucleation, external beam radiation therapy, radioactive plaques (I-125 brachytherapy), cryotherapy, laser photoablation, and chemotherapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall five-year survival rate for children with retinoblastoma in the United States is &gt;90 percent. Patients who develop metastatic disease usually do so within one year of diagnosis; a child who remains recurrence free for five years after diagnosis is considered cured. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Long-term outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term survivors of hereditary retinoblastoma have a lifelong increased risk of second malignancy, including both sarcomas (which are often related to radiation therapy as part of their original treatment) and epithelial malignancies (bladder, breast, lung, skin). Survivors should avoid carcinogenic exposures, such as smoking, and should be monitored for the development of second malignancies. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Second malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up is best accomplished by a multidisciplinary team. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Long-term follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87370388\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Ronald Teed, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/1\">",
"      Dryja TP, Morrow JF, Rapaport JM. Quantification of the paternal allele bias for new germline mutations in the retinoblastoma gene. Hum Genet 1997; 100:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/2\">",
"      Dryja TP, Mukai S, Petersen R, et al. Parental origin of mutations of the retinoblastoma gene. Nature 1989; 339:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/3\">",
"      Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009; 93:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/4\">",
"      Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics 2003; 112:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/5\">",
"      Abramson DH, Ellsworth RM, Grumbach N, et al. Retinoblastoma: correlation between age at diagnosis and survival. J Pediatr Ophthalmol Strabismus 1986; 23:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/6\">",
"      Seregard S, Lundell G, Svedberg H, Kivel&auml; T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology 2004; 111:1228.",
"     </a>",
"    </li>",
"    <li>",
"     Age-adjusted and age-specific SEER cancer incidence rates, 2004-2008. file://seer.cancer.gov/csr/1975_2008/results_merged/sect_29_childhood_cancer_iccc.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/8\">",
"      Binder PS. Unusual manifestations of retinoblastoma. Am J Ophthalmol 1974; 77:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/9\">",
"      Zakka KA, Yee RD, Foos RY. Retinoblastoma in a 12-year-old girl. Ann Ophthalmol 1983; 15:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/10\">",
"      Shields JA, Michelson JB, Leonard BC, Thompson R. Retinoblastoma in an eighteen-year-old male. J Pediatr Ophthalmol 1976; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/11\">",
"      Shields CL, Shields JA, Shah P. Retinoblastoma in older children. Ophthalmology 1991; 98:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/12\">",
"      Takahashi T, Tamura S, Inoue M, et al. Retinoblastoma in a 26-year-old adult. Ophthalmology 1983; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/13\">",
"      Biswas J. Unilateral retinoblastoma in an adult. Ophthalmology 1997; 104:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/14\">",
"      Berkeley JS, Kalita BC. Retinoblastoma in an adult. Lancet 1977; 2:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/15\">",
"      Rubenfeld M, Abramson DH, Ellsworth RM, Kitchin FD. Unilateral vs. bilateral retinoblastoma. Correlations between age at diagnosis and stage of ocular disease. Ophthalmology 1986; 93:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/16\">",
"      Francke U, Kung F. Sporadic bilateral retinoblastoma and 13q- chromosomal deletion. Med Pediatr Oncol 1976; 2:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/17\">",
"      Motegi T. Lymphocyte chromosome survey in 42 patients with retinoblastoma: effort to detect 13q14 deletion mosaicism. Hum Genet 1981; 58:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/18\">",
"      Kivel&auml; T, Tuppurainen K, Riikonen P, Vapalahti M. Retinoblastoma associated with chromosomal 13q14 deletion mosaicism. Ophthalmology 2003; 110:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/19\">",
"      Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res 2012; 2:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/20\">",
"      Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/21\">",
"      Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/22\">",
"      DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 1988; 41:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/23\">",
"      Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 2001; 108:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/24\">",
"      Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99:24.",
"     </a>",
"    </li>",
"    <li>",
"     Vogel F.. Genetics of retinoblastoma. In: Human Genetics: Problems and Approaches, Springer-Verlag, New York 1979. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/26\">",
"      Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol 2002; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/27\">",
"      Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/28\">",
"      Fung YK, Murphree AL, T'Ang A, et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987; 236:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/29\">",
"      Lee WH, Bookstein R, Hong F, et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235:1394.",
"     </a>",
"    </li>",
"    <li>",
"     Hurwitz RL, Shields CL, Shields JA, et al.. Retinoblastoma. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.809.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/31\">",
"      Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 1985; 82:6216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/32\">",
"      Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975; 72:5116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/33\">",
"      Hethcote HW, Knudson AG Jr. Model for the incidence of embryonal cancers: application to retinoblastoma. Proc Natl Acad Sci U S A 1978; 75:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/34\">",
"      Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/35\">",
"      Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/36\">",
"      Smith BJ, O'Brien JM. The genetics of retinoblastoma and current diagnostic testing. J Pediatr Ophthalmol Strabismus 1996; 33:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/37\">",
"      Otterson GA, Chen Wd, Coxon AB, et al. Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. Proc Natl Acad Sci U S A 1997; 94:12036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/38\">",
"      Cast&eacute;ra L, Sabbagh A, Dehainault C, et al. MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst 2010; 102:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/39\">",
"      Sanborn GE, Augsburger JJ, Shields JA. Spontaneous regression of bilateral retinoblastoma. Br J Ophthalmol 1982; 66:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/40\">",
"      Kao LY, Yang ML. Spontaneous regression of retinoblastoma in a Taiwan series. J Pediatr Ophthalmol Strabismus 2005; 42:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/41\">",
"      Khodadoust AA, Roozitalab HM, Smith RE, Green WR. Spontaneous regression of retinoblastoma. Surv Ophthalmol 1977; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/42\">",
"      Singh AD, Santos CM, Shields CL, et al. Observations on 17 patients with retinocytoma. Arch Ophthalmol 2000; 118:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/43\">",
"      Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996; 77:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/44\">",
"      Butros LJ, Abramson DH, Dunkel IJ. Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences. Pediatrics 2002; 109:E45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/45\">",
"      Abramson DH, Marks RF, Ellsworth RM, et al. The management of unilateral retinoblastoma without primary enucleation. Arch Ophthalmol 1982; 100:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/46\">",
"      Margo CE, Zimmerman LE. Retinoblastoma: the accuracy of clinical diagnosis in children treated by enucleation. J Pediatr Ophthalmol Strabismus 1983; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/47\">",
"      Shields CL, Shields JA, Shields MB, Augsburger JJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 1987; 94:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/48\">",
"      Shields JA, Shields CL, Parsons HM. Differential diagnosis of retinoblastoma. Retina 1991; 11:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/49\">",
"      Yoshizumi MO, Thomas JV, Smith TR. Glaucoma-inducing mechanisms in eyes with retinoblastoma. Arch Ophthalmol 1978; 96:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/50\">",
"      Abramson DH. Retinoblastoma 1990: diagnosis, treatment, and implications. Pediatr Ann 1990; 19:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/51\">",
"      Shields CL, Ghassemi F, Tuncer S, et al. Clinical spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes. Ophthalmology 2008; 115:2253.",
"     </a>",
"    </li>",
"    <li>",
"     Lohmann DR, Gallie BL. Retinoblastoma.  In: GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1452/ (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/53\">",
"      Arrigg PG, Hedges TR 3rd, Char DH. Computed tomography in the diagnosis of retinoblastoma. Br J Ophthalmol 1983; 67:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/54\">",
"      Shields CL, Schoenberg E, Kocher K, et al. Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases: results based on age at presentation. Ophthalmology 2013; 120:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/55\">",
"      Abramson DH, Frank CM, Susman M, et al. Presenting signs of retinoblastoma. J Pediatr 1998; 132:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/56\">",
"      Malkani I, Warrier RP, Yu LC, Ode DL. Retinoblastoma: a review. Indian J Pediatr 1993; 60:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/57\">",
"      Char DH, Hedges TR 3rd, Norman D. Retinoblastoma. CT diagnosis. Ophthalmology 1984; 91:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/58\">",
"      Kaste SC, Jenkins JJ 3rd, Pratt CB, et al. Retinoblastoma: sonographic findings with pathologic correlation in pediatric patients. AJR Am J Roentgenol 2000; 175:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/59\">",
"      Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/60\">",
"      Benz MG, Benz MW. Reduction of cancer risk associated with pediatric computed tomography by the development of new technologies. Pediatrics 2004; 114:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/61\">",
"      Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics 2003; 112:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/62\">",
"      de Graaf P, G&ouml;ricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol 2012; 42:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/63\">",
"      Pesin SR, Shields JA. Seven cases of trilateral retinoblastoma. Am J Ophthalmol 1989; 107:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/64\">",
"      Bader JL, Meadows AT, Zimmerman LE, et al. Bilateral retinoblastoma with ectopic intracranial retinoblastoma: trilateral retinoblastoma. Cancer Genet Cytogenet 1982; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/65\">",
"      Kivel&auml; T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999; 17:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/66\">",
"      Karatza EC, Shields CL, Flanders AE, et al. Pineal cyst simulating pinealoblastoma in 11 children with retinoblastoma. Arch Ophthalmol 2006; 124:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/67\">",
"      Pratt CB, Meyer D, Chenaille P, Crom DB. The use of bone marrow aspirations and lumbar punctures at the time of diagnosis of retinoblastoma. J Clin Oncol 1989; 7:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/68\">",
"      Mohney BG, Robertson DM. Ancillary testing for metastasis in patients with newly diagnosed retinoblastoma. Am J Ophthalmol 1994; 118:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/69\">",
"      MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblastoma. Arch Ophthalmol 1984; 102:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/70\">",
"      Palazzi M, Abramson DH, Ellsworth RM. Endophytic vs exophytic unilateral retinoblastoma: is there any real difference? J Pediatr Ophthalmol Strabismus 1990; 27:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/71\">",
"      Smith EV, Gragoudas ES, Kolodny NH, D'Amico DJ. Magnetic resonance imaging: an emerging technique for the diagnosis of ocular disorders. Int Ophthalmol 1990; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/72\">",
"      Azar D, Donaldson C, Dalla-Pozza L. Questioning the need for routine bone marrow aspiration and lumbar puncture in patients with retinoblastoma. Clin Experiment Ophthalmol 2003; 31:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/73\">",
"      Sage J, Cleary ML. Genomics: The path to retinoblastoma. Nature 2012; 481:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/74\">",
"      Dhar SU, Chintagumpala M, Noll C, et al. Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol 2011; 129:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/75\">",
"      Noorani HZ, Khan HN, Gallie BL, Detsky AS. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 1996; 59:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/76\">",
"      Pratt CB, Fontanesi J, Lu X, et al. Proposal for a New Staging Scheme for Intraocular and Extraocular Retinoblastoma Based on an Analysis of 103 Globes. Oncologist 1997; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/77\">",
"      Shields CL, Mashayekhi A, Demirci H, et al. Practical approach to management of retinoblastoma. Arch Ophthalmol 2004; 122:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/78\">",
"      Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/79\">",
"      Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/80\">",
"      Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus 2000; 37:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/81\">",
"      Messmer EP, Heinrich T, H&ouml;pping W, et al. Risk factors for metastases in patients with retinoblastoma. Ophthalmology 1991; 98:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/82\">",
"      Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol 1999; 83:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/83\">",
"      Erwenne CM, Franco EL. Age and lateness of referral as determinants of extra-ocular retinoblastoma. Ophthalmic Paediatr Genet 1989; 10:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/84\">",
"      Stevenson KE, Hungerford J, Garner A. Local extraocular extension of retinoblastoma following intraocular surgery. Br J Ophthalmol 1989; 73:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/85\">",
"      Shields CL, Honavar S, Shields JA, et al. Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology 2000; 107:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/86\">",
"      Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 1998; 105:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/87\">",
"      Moll AC, Imhof SM, Bouter LM, Tan KE. Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet 1997; 18:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/88\">",
"      Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994; 73:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/89\">",
"      Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993; 77:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/90\">",
"      Shields JA. Misconceptions and techniques in the management of retinoblastoma. The 1992 Paul Henkind Memorial Lecture. Retina 1992; 12:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/91\">",
"      Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999; 36:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/92\">",
"      Uusitalo M, Wheeler S, O'Brien JM. New approaches in the clinical management of retinoblastoma. Ophthalmol Clin North Am 1999; 12:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/93\">",
"      Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002; 120:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/94\">",
"      Chantada G, Fandi&ntilde;o A, D&aacute;vila MT, et al. Results of a prospective study for the treatment of retinoblastoma. Cancer 2004; 100:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/95\">",
"      Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011; 129:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/96\">",
"      Kim JW, Kathpalia V, Dunkel IJ, et al. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 2009; 93:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/97\">",
"      Blach LE, McCormick B, Abramson DH. External beam radiation therapy and retinoblastoma: long-term results in the comparison of two techniques. Int J Radiat Oncol Biol Phys 1996; 35:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/98\">",
"      Hernandez JC, Brady LW, Shields JA, et al. External beam radiation for retinoblastoma: results, patterns of failure, and a proposal for treatment guidelines. Int J Radiat Oncol Biol Phys 1996; 35:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/99\">",
"      Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/100\">",
"      Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997; 104:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/101\">",
"      O'Brien JM, Smith BJ. Chemotherapy in the treatment of retinoblastoma. Int Ophthalmol Clin 1996; 36:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/102\">",
"      Singh AD, Garway-Heath D, Love S, et al. Relationship of regression pattern to recurrence in retinoblastoma. Br J Ophthalmol 1993; 77:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/103\">",
"      Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/104\">",
"      Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/105\">",
"      Mohney BG, Robertson DM, Schomberg PJ, Hodge DO. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 1998; 126:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/106\">",
"      Wilson MW, Rodriguez-Galindo C, Haik BG, et al. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 2001; 108:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/107\">",
"      Brooks HL Jr, Meyer D, Shields JA, et al. Removal of radiation-induced cataracts in patients treated for retinoblastoma. Arch Ophthalmol 1990; 108:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/108\">",
"      Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol 1997; 15:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/109\">",
"      Stannard C, Sealy R, Hering E, et al. Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/110\">",
"      Shields CL, Shields JA, De Potter P, et al. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology 1993; 100:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/111\">",
"      Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 2001; 108:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/112\">",
"      Schueler AO, Fl&uuml;hs D, Anastassiou G, et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. Int J Radiat Oncol Biol Phys 2006; 65:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/113\">",
"      Abouzeid H, Moeckli R, Gaillard MC, et al. (106)Ruthenium brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys 2008; 71:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/114\">",
"      Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/115\">",
"      Baumal CR, Shields CL, Shields JA, Tasman WS. Surgical repair of rhegmatogenous retinal detachment after treatment for retinoblastoma. Ophthalmology 1998; 105:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/116\">",
"      Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003; 21:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/117\">",
"      Chantada GL, Fandi&ntilde;o AC, Casak SJ, et al. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/118\">",
"      Mallipatna AC, Dimaras H, Chan HS, et al. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 2011; 129:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/119\">",
"      Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 2009; 50:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/120\">",
"      Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol 2008; 19:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/121\">",
"      Schouten-Van Meeteren AY, Moll AC, Imhof SM, Veerman AJ. Overview: chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol 2002; 38:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/122\">",
"      Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002; 120:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/123\">",
"      Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/124\">",
"      Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 2004; 138:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/125\">",
"      Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/126\">",
"      Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009; 116:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/127\">",
"      Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 2005; 123:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/128\">",
"      Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001; 119:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/129\">",
"      Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007; 114:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/130\">",
"      Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/131\">",
"      Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999; 106:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/132\">",
"      Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/133\">",
"      Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 2011; 129:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/134\">",
"      Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/135\">",
"      Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011; 129:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/136\">",
"      Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011; 129:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/137\">",
"      Peterson EC, Elhammady MS, Quintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 2011; 114:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/138\">",
"      Shields CL, Kaliki S, Shah SU, et al. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology 2012; 119:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/139\">",
"      Levin MH, Gombos DS, O'Brien JM. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol 2011; 129:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/140\">",
"      Wilson MW, Haik BG, Dyer MA. Superselective intraophthalmic artery chemotherapy: what we do not know. Arch Ophthalmol 2011; 129:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/141\">",
"      Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 2011; 129:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/142\">",
"      Eagle RC Jr, Shields CL, Bianciotto C, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2011; 129:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/143\">",
"      Munier FL, Beck-Popovic M, Balmer A, et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina 2011; 31:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/144\">",
"      Vijayakrishnan R, Shields CL, Ramasubramanian A, et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol 2010; 128:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/145\">",
"      Shields CL, Ramasubramanian A, Rosenwasser R, Shields JA. Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma. Retina 2009; 29:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/146\">",
"      Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer 2000; 89:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/147\">",
"      Shields CL, Santos MC, Diniz W, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol 1999; 117:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/148\">",
"      Abramson DH, Schefler AC. Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma: technique and predictors of success. Ophthalmology 2004; 111:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/149\">",
"      Kremens B, Wieland R, Reinhard H, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 2003; 31:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/150\">",
"      Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 1997; 33:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/151\">",
"      Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 2003; 33:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/152\">",
"      Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009; 93:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/153\">",
"      Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology 1987; 94:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/154\">",
"      Schvartzman E, Chantada G, Fandi&ntilde;o A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol 1996; 14:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/155\">",
"      Pratt CB, Fontanesi J, Chenaille P, et al. Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol 1994; 11:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/156\">",
"      Chantada G, Fandi&ntilde;o A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 2003; 40:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/157\">",
"      Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique. J Clin Oncol 1995; 13:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/158\">",
"      Blach LE, McCormick B, Abramson DH, Ellsworth RM. Trilateral retinoblastoma--incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys 1994; 29:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/159\">",
"      Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008; 100:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/160\">",
"      Qiao YL, Dawsey SM, Kamangar F, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 2009; 101:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/161\">",
"      Woo KI, Harbour JW. Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. Arch Ophthalmol 2010; 128:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/162\">",
"      Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/24/27018/abstract/163\">",
"      Bagley LJ, Hurst RW, Zimmerman RA, et al. Imaging in the trilateral retinoblastoma syndrome. Neuroradiology 1996; 38:166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6275 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5CB361C86E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27018=[""].join("\n");
var outline_f26_24_27018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sporadic versus inherited disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Morphologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MOLECULAR GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLASSIFICATION AND PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Enucleation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      External beam RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radioactive plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cryotherapy and laser photocoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chemoreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3851122\">",
"      Local chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Potential future therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      LONG-TERM FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87370388\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6275|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/44/8898\" title=\"diagnostic image 1\">",
"      Calcified intraorbital mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/3/38962\" title=\"diagnostic image 2\">",
"      Coats disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6275|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/36/8782\" title=\"figure 1\">",
"      Retinoblastoma less than 8yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/3/13374\" title=\"figure 2\">",
"      Retinoblastoma less than 3yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/30/28131\" title=\"figure 3\">",
"      Retinoblastoma formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6275|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/7/124\" title=\"picture 1\">",
"      Leukocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/19/41278\" title=\"picture 2\">",
"      Retinoblastoma strabismus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/16/44302\" title=\"picture 3\">",
"      Combined exophytic-endophytic retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/39/28284\" title=\"table 1\">",
"      Risk of retinoblastoma in offspring and siblings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19837\" title=\"table 2\">",
"      Genetic testing in retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/33/40476\" title=\"table 3\">",
"      Int class retinoblastoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=related_link\">",
"      Approach to the child with leukocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_24_27019="Total fetal loss rate3";
var content_f26_24_27019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Total fetal loss rate: TC CVS compared with TA CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study, year",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total loss rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Difference percentage",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Relative risk, 95 percent CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TC CVS",
"       </td>",
"       <td class=\"subtitle2\">",
"        TA CVS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brambati (1991)",
"       </td>",
"       <td>",
"        16.0 (95/592)",
"       </td>",
"       <td>",
"        17.3 (102/591)",
"       </td>",
"       <td>",
"        -1.2",
"       </td>",
"       <td>",
"        0.9 (0.7-1.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smidt-Jensen (1992)",
"       </td>",
"       <td>",
"        12.4 (188/1514)",
"       </td>",
"       <td>",
"        7.4 (113/1527)",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        1.7 (1.3-2.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jackson (1992)",
"       </td>",
"       <td>",
"        4.0 (74/1846)",
"       </td>",
"       <td>",
"        4.1 (72/1744)",
"       </td>",
"       <td>",
"        -0.1",
"       </td>",
"       <td>",
"        1.0 (0.8-1.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        1.2 (1.1-1.4)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27019=[""].join("\n");
var outline_f26_24_27019=null;
var title_f26_24_27020="Dx of TB pleuritis in HIV";
var content_f26_24_27020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic tests of tuberculous pleural effusion in HIV-infected patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Pleural fluid",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Pleural biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        AFB smear +/T (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Culture +/T (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        AFB smear +/T (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Culture +/T (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Histology +/T (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kitinya, JN, Richter, C, Perenboom, R. Tubercle Lung Dis 1994; 75:195",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        12/36 (33)*",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        20/56 (56)&bull;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Relkin, F, Aranda, CP, Garay, SM. Chest 1994; 105:1338",
"       </td>",
"       <td>",
"        6/40 (15)",
"       </td>",
"       <td>",
"        39/43 (91)",
"       </td>",
"       <td>",
"        11/16 (69)",
"       </td>",
"       <td>",
"        7/15 (47)",
"       </td>",
"       <td>",
"        14/16 (88)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frye, MD, Pozsik, CJ, Sahn, SA. Chest 1995; 108:102S",
"       </td>",
"       <td>",
"        1/16 (16)",
"       </td>",
"       <td>",
"        9/14 (64)",
"       </td>",
"       <td>",
"        4/9 (44)",
"       </td>",
"       <td>",
"        2/5 (40)",
"       </td>",
"       <td>",
"        7/9 (77)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gil, V, Cordero, PJ, Greses, JV, Soler, JJ. Chest 1995; 107:1775",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4/9 (44)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4/9 (44)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total",
"       </td>",
"       <td>",
"        7/56 (12.5)",
"       </td>",
"       <td>",
"        64/102 (63)",
"       </td>",
"       <td>",
"        15/25 (60)",
"       </td>",
"       <td>",
"        29/76 (38)",
"       </td>",
"       <td>",
"        25/34 (74)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Results in non-HIV-infected patients",
"       </td>",
"       <td>",
"        12/55 (22)",
"       </td>",
"       <td>",
"        150/356 (42)",
"       </td>",
"       <td>",
"        20/76 (26)",
"       </td>",
"       <td>",
"        48/75 (64)",
"       </td>",
"       <td>",
"        68/95 (72)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: positive, T: total.",
"     <br>",
"      * Pleural fluid AFB smear or culture positive.",
"      <br>",
"       &bull; Pleural biopsy AFB smear or culture positive.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27020=[""].join("\n");
var outline_f26_24_27020=null;
var title_f26_24_27021="2002 TNM staging stomach CA";
var content_f26_24_27021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Joint Committee on cancer staging for gastric cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\" rowspan=\"1\">",
"       Tumor (T) stage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1s",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Carcinoma in situ: intra-epithelial tumor without invasion of the lamina propia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Tumor invades lamina propria or submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\" rowspan=\"1\">",
"       Tumor invades muscularis propria or subserosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\" rowspan=\"1\">",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\" rowspan=\"1\">",
"       Tumor invades subserosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Tumor penetrates serosa (visceral peritoneum) without invasion of adjacent structures*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Tumor invades adjacent structures*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\" rowspan=\"1\">",
"       Nodal (N) stage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Regional lymph node(s) cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Metastasis in 1 to 6 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Metastasis in 7 to 15 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Metastasis in more than 15 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\" rowspan=\"1\">",
"       Metastasis (M) stage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mx",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Presence of distant metastasis cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\" rowspan=\"1\">",
"       Stage grouping",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 1A",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Stage 1B",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2a/b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Stage II",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2a/b",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T2a/b",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Stage IV",
"      </td>",
"      <td>",
"       T1-3",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N1-3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in amy of these sites, including the stomach.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27021=[""].join("\n");
var outline_f26_24_27021=null;
var title_f26_24_27022="Trandolapril lowers mortality after MI";
var content_f26_24_27022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long-term mortality after myocardial infarction is reduced by trandolapril",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 456px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 1749 patients in the TRACE study followed for a minimum of six years, treatment with trandolapril improved life expectancy by 15.3 months (6.2 versus 4.6 years for placebo). The number of lives saved per 1000 people treated are shown for each year.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Torp-Pederson C, Kober L, for the TRACE Study Group. Lancet 1999; 354:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27022=[""].join("\n");
var outline_f26_24_27022=null;
var title_f26_24_27023="Action potential and ECG";
var content_f26_24_27023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between myocardial action potential and surface electrocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each phase of the myocardial action potential (numbers, upper panel) corresponds to a deflection or interval on the surface electrocardiogram (lower panel). Phase 4, the resting membrane potential, is responsible for the TQ segment; this segment has a prominent role in the ECG manifestations of ischemia during exercise testing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_24_27023=[""].join("\n");
var outline_f26_24_27023=null;
